Molecular mechanisms of antibody diversification in human B-cells by Björkman, Andrea
  
From the Department of Laboratory Medicine 
Karolinska Institutet, Stockholm, Sweden 
MOLECULAR MECHANISMS OF 
ANTIBODY DIVERSIFICATION IN HUMAN 
B-CELLS 
Andrea Björkman 
 
Stockholm 2015 
 
  
 
 
 
 
 
 
 
 
 
 
All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by E-Print, Stockholm, Sweden 
© Andrea Björkman, 2015 
ISBN 978-91-7549-966-6 
  
 
 
 
 
Institutionen för Laboratoriemedicin 
Molecular mechanisms of antibody 
diversification in human B-cells 
 
AKADEMISK  AVHANDLING 
som för avläggande av medicine doktorsexamen vid Karolinska Institutet 
offentligen försvaras i Föreläsningssalen 9Q Månen, Nobels Allé 8, plan 
9, Karolinska Institutet, Huddinge.  
Fredagen den 5 juni, 2015, kl. 10:00 
av 
Andrea Björkman 
 
 
 
 
Stockholm 2015 
Huvudhandledare:  
Professor Qiang Pan-Hammarström 
Karolinska Institutet 
Institutionen för Laboratoriemedicin 
 
Bihandledare:  
Professor Lennart Hammarström 
Karolinska Institutet 
Institutionen för Laboratoriemedicin 
 
Professor Camilla Sjögren 
Karolinska Institutet 
Institutionen för Cell- och Molekylärbiologi 
Fakultetsopponent: 
Assistant Professor Shan Zha 
Columbia University 
Department of Pathology and Cell biology  
 
Betygsnämnd: 
Professor Rolf Ohlsson 
Karolinska Institutet 
Institutionen för mikrobiologi, tumör- och 
cellbiologi 
 
Professor Thomas Grundström 
Umeå universitet 
Institutionen för Molekylärbiologi 
 
Docent Mats Bemark 
Göteborgs universitet 
Institutionen för Biomedicin 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my family 
 
 
  
ABSTRACT 
B-cells undergo several somatic rearrangement/mutational processes during development to 
diversify their immunoglobulin (Ig) receptors. First, the antigen binding Ig variable (V) 
region is assembled through V(D)J recombination. Later, B-cells undergo class switch 
recombination (CSR), which exchanges the constant region and thus Ig isotype and immune 
effector function. In addition, point mutations are introduced into the Ig V regions, to increase 
the affinity between the Ig and antigen, by somatic hypermutation (SHM). These processes 
rely on numerous DNA damage response (DDR) and DNA repair proteins, such as those 
from the classical non-homologous end-joining (c-NHEJ) pathway. The aim of this thesis 
was to elucidate the functions of some of these proteins during antibody diversification in 
human cells.  
In Paper I, cells from patients with Cornelia de Lange syndrome (CdLS), with mutations in 
the gene encoding the cohesin loader NIPBL, were studied. The analysis of CSR junctions 
from these patients revealed an altered repair pattern. It was characterized by reduced direct 
end-joining and increased microhomology (MH) usage, indicating a shift from c-NHEJ to 
alternative end-joining (A-EJ). A role for NIPBL in promoting NHEJ was shown to be 
conserved in yeast. Furthermore, the early recruitment of the DDR factor 53BP1 to DSBs was 
impaired in the NIPBL-deficient cells, suggesting a mechanism for the involvement of 
NIPBL/cohesin in NHEJ. 
In Paper II, the Ig heavy (H) chain and T cell receptor (TCR)  chain V region repertoires 
were analyzed in CdLS patients by high through-put sequencing methods. The cells from the 
CdLS patients showed reduced lymphocyte receptor diversity and a skewed V gene usage, 
which seemed dependent on the location of the genes at the IgH and TCR loci. Furthermore, 
the frequency of SHMs in the IgH V regions was reduced. These results might imply a role 
for cohesin in the regulation of SHM, as well as in processes ensuring that V genes 
throughout the Ig locus are used during V(D)J recombination.  
In Paper III, the CSR junctions were analyzed in individuals deficient in the tumor 
suppressor BRCA1. The CSR junctions showed several aberrations, including increased MH 
usage, elevated frequency of intra-switch deletions and unusual insertions containing 
inversions. Alterations were also observed at the CSR-junctions from patients with defects in 
the BRCA1-associated proteins BRIP1, BRCA2, CtIP and RNF168. Thus, it seems as 
BRCA1 together with its interaction partners play an important role in promoting the c-NHEJ 
pathway during CSR. 
In Paper IV, CSR junctions were examined in the two only patients described with DNA-
PKcs-deficiency to date. Furthermore, CSR-junctions from DNA-PKcs-deficient mice and 
the Ramos B-cell line, transfected with a switch plasmid and treated with DNA-PKcs 
inhibitor, were studied. The role of DNA-PKcs in CSR has been unclear, but the analysis of 
CSR junctions from all DNA-PKcs-deficient models revealed a shift to A-EJ, suggesting that 
CSR, indeed, is affected in DNA-PKcs-deficient cells.  
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1 INTRODUCTION 
 
1.1 THE ADAPTIVE IMMUNE SYSTEM 
 
Most multicellular organisms, ranging from plants and insects to birds and mammals, have 
developed immune systems to protect themselves from outside invaders.
1
 It requires the 
ability to distinguish foreign molecules, such as pathogenic agents (pathogens) including 
viruses, bacteria, fungi and parasites, from the host organism’s own components and the 
capacity to eliminate the pathogens.  
The first type of defense that developed during evolution is the innate immune system.
1
 It 
acts immediately upon an infection and recognizes structures that are shared among groups of 
pathogens. It includes anatomical barriers, such as the skin and mucosal surfaces, as well as 
pattern recognition receptors that bind motifs that are present on infectious organisms and 
signals to the immune system.
2
 Furthermore, specialized immune cells, including phagocytes, 
which can ingest pathogens and natural killer cells, which kill infected cells, belong to the 
innate immune system.
1
 
A second immune branch started to develop in jawless fishes, the adaptive immune system, 
which exists in vertebrates.
3
 The adaptive immune system requires longer time to react 
compared to the innate immune system, but can develop recognition of specific infectious 
microorganisms. Furthermore, this specificity can be stored in memory cells that can quickly 
start an immune response if the host encounters the same pathogen later in life. The adaptive 
immune system consists of two cell lineages: B and T lymphocytes. 
Nevertheless, the innate and adaptive immune branches are dependent on each other and 
cross talk occurs between them. A component of the innate immune system, which plays a 
role in connecting the two systems, is the dendritic cell. Dendritic cells present antigens, parts 
of (mostly) foreign molecules, to lymphocytes and can activate the adaptive immune 
response.
4
 Furthermore, immune cells with characteristics of both branches have been 
discovered, such as innate lymphoid cells, which are lymphocytes without a particular 
antigen specificity
5
 and invariant NKT cells, resembling both NK and T cells.
6
 
 
1.1.1 B lymphocytes 
The B cell was named after the avian organ bursa of Fabricius, in which it was first 
discovered.
7
 The letter B also coincides with its developmental origin in mammals, the bone 
marrow. However, long before the B cell was revealed, antibodies or immunoglobulins (Igs), 
which are produced by B-cells, were described. In 1890, Emil von Behring and Shibasaburo 
Kitasato termed them antitoxins, since they could neutralize the toxins of diphtheria and 
 2 
 
tetanus.
8
 Later, the components of Igs were elucidated and it was found that Igs were 
composed of three fragments. One of these, the Fc (crystallizable fragment) or constant (C) 
region, conferred the Igs immune effector functions, whereas the other two were antigen-
binding (Fabs) and contained the variable (V) region.
9
 The Ig V region can bind to various 
types of antigen structures, including proteins, polysaccharides, lipids and nucleic acids. The 
Ig composition can also be described as consisting of two identical heavy (H) chains 
comprised of V and C regions, either (IgM),  (IgG),  (IgA) or  (IgE) and two identical 
light (L) chains,  or which are attached by disulfide bonds (Fig. 1). Igs can either act as 
receptors, when bound to the B cell membrane, or be secreted from the cells in their soluble 
form.  
The different Ig classes have various biological functions and distributions within the body. 
IgM and IgD are the first Ig classes expressed, whereas IgG is the most prevalent Ig in 
serum.
10
 In contrast, on mucosal surfaces IgA is most predominant,
11
 whereas IgE has the 
lowest overall abundance and seems to mainly function in the defense against parasites, as 
well as in mediating allergic reactions.
12
 Igs can have neutralizing effects by encircling or 
binding to toxins or viruses and thereby inhibit their functions.
11
 Furthermore, Igs may mark 
pathogens for targeting of innate immune cells, such as phagocytes, neutrophils and NK cells, 
as well as activate immune functions, including the complement system.
10
  
 
Figure 1: The B and T cell receptors 
Schematic picture of immunoglobulin (Ig) is shown to the left. Constant (C) regions are depicted in blue and the 
variable (V) regions, binding an antigen (blue circle), in red and purple. The Ig consists of two identical heavy 
chains and two identical light chains. A T-cell receptor composed of  chains is shown to the right. Each chain 
is composed of a C region and a V region and the latter binds to an antigen presented by an MHC-molecule.  
 
1.1.1.1 The clonal selection theory 
The discovery of Igs created a new puzzle regarding how the Igs could become so diverse 
that they could theoretically recognize all pathogens. Some immunologists believed that the 
antigens themselves served as templates for instructing the B-cells to produce antibodies that 
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could bind to them (the instructive theories).
13
 Others argued that the antigens bound to Igs 
that already preexisted in the organism (the selective theories). A follower of the latter was 
Frank Macfarlane Burnet who, in 1957, proposed the clonal selection theory.
14
 According to 
this theory, B-cells with a great variety of antigen specificities already exist in the body and 
each B cell only confers a single specificity. Furthermore, those cells that carry receptors that 
do not bind antigens will be eliminated, whereas the cells that carry receptors that bind to 
antigens will expand. A year later it was also shown experimentally that one B cell only 
produces one antibody specificity.
15
 
 
1.1.1.2 B cell development 
A B cell can go through several developmental and maturation stages and many of them are 
dependent on somatic DNA rearrangement/mutational processes that will diversify their Ig 
receptors.
16
 These include V(D)J recombination, which assembles the H and L chains, class 
switch recombination (CSR), which exchanges the Ig isotype, and somatic hypermutation 
(SHM), which can improve the affinity between the antibody and antigen (Fig. 2).  
 
Figure 2. The antibody diversification processes V(D)J recombination, class switch recombination and 
somatic hypermutation. V(D)J recombination occurs in the bone marrow and assembles V, D and J genes 
through a deletion/recombination process initiated by the RAG1 and RAG2 enzymes, into the Ig V region. In the 
germinal center, CSR is initiated by AID and here exemplified by the exchange of the C region gene with the 
C1 region gene in a recombination/deletion process, resulting in an exchange of IgM to IgA isotype expression. 
In the germinal center, AID also initiates SHM, which introduces point mutations, marked by starts, in the Ig V 
region to increase the affinity between the Ig and antibody.  
The hematopoietic precursor cells that give rise to B-cells reside in the bone marrow.
17
 The 
developmental process begins at the pro-B cell stage by the assembly of the H chain by J-D, 
followed by JD-V, rearrangement.
16
 The L chain is rearranged through V-J recombination 
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during the pre-B cell stage and when this process is completed, the B-cell has reached the 
immature B-cell stage. Subsequently, the B cell is tested against self-antigens and if it binds 
to self it will not continue the maturation process. Instead, it could undergo receptor-editing, 
during which the B-cell rearranges its L chain a second time to change its specificity.
18
 This 
check point ensures that only B-cells that are tolerant to the organism’s own components, will 
exit the bone marrow. If the B-cell encounters an antigen that can bind to its receptor, it will 
become activated and migrate to germinal centers, which are structures in secondary 
lymphoid organs, such as the spleen, lymph nodes and Peyer’s patches in the intestine.19 
There it will proliferate, as well as go through SHM and CSR. The B-cells can thereafter 
mature into plasma cells, excreting Igs, or memory B-cells, which will reside in the organism 
and can become activated if they encounter antigens later in life.  
 
1.1.2 T lymphocytes 
Although T-cells originate from the bone marrow, they received their names from the organ 
where most of their development occurs, the thymus.
20
 Similarly to B-cells, T-cells express 
receptors, T-cell receptors (TCRs), which can bind to antigen. However, in contrast to B-
cells, the TCRs are always attached to the T-cell membrane. Furthermore, the TCR only 
binds to a small peptide of the antigen that has been presented to it by a major 
histocompatibility complex (MHC) molecule.
21
 MHC class I molecules are present on nearly 
all the cells within the organism and are recognized by CD8
+
 T-cells, which are mostly 
referred to as cytotoxic T-cells.
20
 The organism’s cells continuously display peptides from 
their intracellular cytoplasm. If a foreign antigen, such as from a virus or tumor is exhibited, 
the cell will be eliminated by the cytotoxic T-cells to prevent further spread of the infection or 
the malignant cells. MHC class II molecules, on the other hand, are only present on 
professional antigen presenting cells, such as dendritic cells and B-cells, which present 
peptides from the extracellular environment. Antigens presented by MHC class II molecules 
are detected by CD4
+ 
T-cells, which are most often referred to as helper T-cells and can aid 
the immune response by secretion of cytokines, signaling molecules that activates immune 
components, such as B-cells.
20
  
The TCR is a heterodimeric glycoprotein consisting of  and  chains, in most T-cells, or  
and  chains, in a subset of cells, connected by disulphide bonds.20 Similarly to the Igs, the 
TCR consists of V and C regions (Fig. 1), of which V binds the MHC-antigen complex, 
whereas the C region is attached to the cell membrane. Unlike Igs, the C region of the TCR 
cannot be exchanged and its V region will not undergo affinity maturation. Since the TCR 
binds both to the antigen and the MHC molecule, its V region specificity is directed to both 
molecules, so called MHC restriction.
20
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1.1.2.1 T-cell development 
The hematopoietic stem cells that give rise to T-cells reside in the bone marrow. However, 
already at the early thymic progenitor stage, these cells migrate to the thymus, where 
rearrangement begins. Pro T-cells, which do not express CD4 or CD8 (double negative), 
undergo TCRrearrangement through D-J followed by V-DJ recombination. Subsequently, 
CD4 and CD8 are expressed (double positive) and TCR V-J rearrangement may begin. 
When the V region assembly is completed, the TCR can undergo positive and negative 
selection, which prevents auto-reactive T-cells from exiting the thymus. T-cells having 
receptors with too high-affinity for the antigen-MHC complex are then eliminated,
21
 whereas 
those that can either bind peptide-MHC class I or II become CD8
+ 
or CD4
+
 T-cells, 
respectively. Finally, the cells can exit to the periphery. Both CD4
+
 and CD8
+
 T-cells can 
develop into memory T-cells.  
 
1.2 V(D)J RECOMBINATION 
 
According to the clonal selection theory, B (and T) cells must produce an immense number of 
different antigen receptors (AgRs). It was long considered an enigma how the B and T-cells 
could produce V regions with such a variability
13
. In the 1970s, when the V(D)J 
recombination process was discovered, the knowledge about the genome and the number of 
genes it contained was limited. Still, it seemed unlikely that our genomes would contain 
millions of genes only to encode the immune system. This paradox was thus explained when 
Susumu Tonegawa presented how V(D)J recombination could give rise to millions of antigen 
specificities from a limited number of genes by assembling different combinations of variable 
(V), diversity (D) and joining (J) genes into the V regions of Igs
22
 (Figure 2). Since then, 
more details have been elucidated regarding the process, such as how the V, D, and J genes 
are targeted, excised and recombined.  
 
1.2.1 The accessibility hypothesis 
All cells carry the genes encoding the Igs and TCRs, but as these are only rearranged and 
expressed in lymphocytes, these genes are tightly packed in chromatin in most cells. In 
lymphocytes, V(D)J recombination must also occur during specific developmental time 
points and a rearrangement resulting in a productive V region may only occur on one allele. 
Thus, according to the “accessibility hypothesis”, proposed more than thirty years ago, 
several processes are involved in making the chromatin embedded genes available to the 
recombination machinery.
23,24
 
The theory arose after the observation of germline (sterile) transcription, which does not 
result in the expression of proteins, during V(D)J recombination.
24,25
 The transcription started 
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at the V gene’s promoter and ended at the recombination site. It has become clear that 
germline transcription is necessary for V(D)J recombination, since the inhibition of 
transcription at the J gene cluster at the TCR locus, completely blocked the recombination 
of the J segments downstream of the inhibition site.
26
 
Another form of transcription, antisense transcription, which occurs in the opposite direction 
and spans several V genes, is also observed during V(D)J recombination.
27
 Apart from 
making the locus accessible, antisense transcription seems to facilitate locus contraction. 
Then several DNA-loops are created, forming a rosette-like structure of the AgR locus
28
. 
Some AgR loci span several 100 kbs and locus contraction ensures that distally located V 
genes get an equal chance for recombination as the proximal V genes. 
In addition, an open chromatin structure is created by histone modifications, such as 
hypermethylation of lysine4 at histone (H) 4 and acetylation of H3/H4 during V(D)J 
recombination.
29
 Moreover, the repositioning of the AgR locus within the nucleus appears to 
be of importance. Accordingly, the IgH and Ig loci have been shown to be located in the 
peripheral parts of the nucleus, with a repressive chromatin environment, in hemapoietic 
progenitors and pro T-cells, but in a central location in pro-B-cells.
30
 
 
1.2.2 RAG-mediated DNA double strand breaks 
When the Ig or TCR locus has become accessible, the lymphocyte specific recombination 
activation gene (RAG) 1
31
 and RAG2
32
 can bind to the locus and initiate the V(D)J 
recombination process. The RAG enzymes bind to specific recombination signal sequences 
(RSS) at the borders of the V-, D- or J-genes that will recombine. The RSS consists of 
conserved AT-rich nonamer and palindromic heptamer motifs, which are adjacent to non-
conserved 12 or 23 bp spacer sequences
33,34
 (Fig. 3). According to the 12/23 rule, only 
spacers of different size can be paired, which guarantees that merely V-D-J (at IgH and 
TCR, ) or V-J (IgL, TCR, ) recombination occurs.  
The RAG complex initiates the DNA double strand break (DSB) formation process by 
inserting a single stranded (ss) nick at the coding strand that creates a free hydroxyl group at 
the 5’end (Fig. 3). The hydroxyl group will subsequently attack the other strand, through a 
trans-esterification reaction, and form a covalently bound hairpin loop at the coding ends, 
which resides in the chromosome. The deleted, extrachromosomal sequence instead contains 
blunt, 5’phosphorylated signal ends.33 
 
1.2.3 Repair of DNA double strand breaks 
DSBs are one of the most severe DNA lesions and if unrepaired they can result in cell death, 
whereas if misrepaired they could cause genomic rearrangements, translocations. DSBs can 
be generated from external and internal stresses to the cell, such as ionizing radiation, free 
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radicals and replication fork collapses.
35
 Moreover, DSBs can be intermediates of 
physiological processes, including V(D)J recombination and CSR. There are two major repair 
pathways of DSBs, non-homologous end-joining (NHEJ) and homologous recombination 
(HR).
35
 
 
 
In brief, HR is initiated by DNA end resection, which creates 3’ ssDNA, followed by strand 
invasion into undamaged, homologous DNA, usually the sister chromatid.
36
 DNA can 
subsequently be copied from the homologous sequence and the newly synthesized strand will 
then dissociate and the DNA ends will be re-ligated. HR relies on numerous proteins, such as 
BRCA1, BRCA2, CtIP and RAD51.
36
 Furthermore, HR is restricted to the S/G2 phases when 
two chromatids are available and it is considered error-free, since any missing information 
can be copied from the other chromatid.  
NHEJ, on the other hand, can act throughout the cell cycle, since it joins the two DNA ends 
directly, or with a few base pairs overlap, so called microhomologies (MHs).
37
 It is seen as 
error-prone as nucleotides can be lost or inserted during the event. The classical NHEJ (c-
NHEJ) factors include Ku70, Ku80, DNA-PKcs, Artemis, DNA ligase IV (Lig4), XRCC4 
and Cernunnos (XLF).
35
 When a c-NHEJ factor is missing, alternative end-joining (A-EJ) 
pathways may act and these often requires longer stretches of MHs to join the broken ends 
(see section 1-3-4). More details about the involvement of c-NHEJ in V(D)J recombination 
and CSR can also be found in sections 1.2.4 and 1.3.3, respectively.  
 
Figure 3. Formation of 
coding and signal joints 
during V(D)J recombination 
The RAG1/2 complex binds at 
RSS sequences at the genes 
that will recombine and 
locates them in close 
proximity in the paired 
complex. Subsequently, the 
RAG enzymes create hairpin 
loops at the chromosomal 
coding ends, whereas blunt 
signal ends in the deleted 
sequence. These are then 
repaired by components from 
the NHEJ pathway. Additional 
diversity is created at the 
coding joint through the 
deletion or insertion of 
nucleotides. 
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1.2.4 Repair of coding and signal joints 
Since RAG2 is only expressed during the G1 cell cycle phase, the RAG-induced DSBs are 
repaired by the c-NHEJ pathway.
38
 Moreover, the RAG enzymes seem to direct the repair to 
the NHEJ pathway.
39,40
 The inherent low-fidelity in the repair process is also suitable for 
creation of additional diversity at the coding junctions.  
As the signal ends are blunt, whereas the coding ends are shielded in the hairpin, the 
resolution and recombination of these structures rely on slightly different sets of DNA repair 
factors. The opening of the hairpin requires the Artemis nuclease,
41
 which depends on DNA-
PKcs for its activation. If the hairpin is opened asymmetrically, it will either result in 
deletions or additions of a few (usually 1-2) palindromic (P) nucelotides. Furthermore, the 
lymphoid-specific enzyme, terminal deoxynucleotidyl transferase (TdT), can add non-
template (N) nucleotides to the junctions. These alterations further add to the diversity of the 
VDJ junctions, so called junctional diversity.
34
 
The repair of coding and signal joints is dependent on the Ku70/80 heterodimer, which seems 
to be the first proteins that bind to the DNA ends.
34
 The DNA ends are subsequently ligated 
by the XRCC4/Lig4/XLF complex. The coding ends also activate factors from the DNA 
damage response (DDR), including Ataxia-telangiectasia mutated (ATM), which stabilizes 
the post cleavage complex.
42
 However, many other DDR factors, such as 53BP1 and H2AX 
seem only to have modest or no impact on the repair during V(D)J recombination.
43
 
Several DDR and NHEJ factors have not been thought to be required for the repair of coding 
and/or signal ends. However, studies on double knock out mouse models have shown that 
their full contributions to the process have been masked by their overlapping functions. 
Consequently, severe V(D)J recombination defects have been revealed in the combined 
deficiency of ATM and DNA-PKcs, which could be due to that they share common 
substrates.
44,45
 Furthermore, although XLF is required for V(D)J recombination in human 
cells,
46
 mouse cells seems to be less dependent on XLF during V(D)J recombination.
47
 
However, redundant functions between XLF and DNA-PKcs
48
 and between XLF and the 
DDR factors 53BP1,
49
 H2AX or ATM
50
 have been revealed. Thus, mice with the combined 
deficiency in XLF or any of the mentioned proteins have striking V(D)J recombination 
defects.  
 
1.3 CLASS SWITCH RECOMBINATION 
 
CSR involves the formation of DSBs in switch (S) regions, intronic sequences located 
upstream of each C region gene. The subsequent synapsis and recombination of the S with 
a downstream S region (S, S or S), result in an exchange of Ig class expression from IgM 
to IgG, IgA or IgE
51,52
 (Fig. 2). The analysis of the repair pattern at the recombined S regions, 
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CSR junctions, may be used to deduce the DNA repair pathways used in CSR.
51
 A shift from 
the direct end-joining to the use of longer MHs often indicates a defect in c-NHEJ.   
 
1.3.1 AID-initiated creation of DNA double strand breaks in switch regions 
CSR, similar to V(D)J recombination, requires germline transcription.
53
 The C promoter is 
constitutively active, whereas the downstream C region promoters are induced by specific 
cytokines.
54
 The C region genes are structured as transcriptional units, starting with a 
promoter, followed by an intervening exon, an intronic S region and ending with the C region 
gene.
54
 The S regions are guanine (G) rich, repetitive sequences essential for CSR. These 
regions increase the occurrence of R-loop formations, DNA:RNA hybrid structures that 
facilitates ssDNA creation and correlates with CSR efficiency.
55,56
 The length of the S 
regions is of relevance for CSR and the longer the S region, the higher is the efficiency of 
switching.
55,57
 One of the main functions of germline transcription seems to be to make the S 
regions accessible for activation induced cytidine deaminase (AID), which only binds to 
ssDNA.
58
 AID appears to be recruited to transcribed genes through its interaction with Spt5, a 
protein associated with stalled RNA polymerase II.
59
 Furthermore, the S regions contain 
numerous RGYW/WRCY (R=purine, Y=pyrimidine, W=A/T) motifs, which contain the AID 
binding hotspots WRC/RGY. However, in contrast to the RAG enzymes, AID does not 
specifically target conserved sequences, but can bind throughout the S regions.   
AID is a B-cell specific molecule and member of the APOBEC family of cytidine 
deaminases.
53
 It initiates the CSR process by deaminating cytosines (C) into uracils (U) in the 
S regions.
60
 AID was discovered more than 15 years ago when its expression was shown to 
be upregulated 10-fold after cytokine stimulation for CSR.
61
 Deficiency in AID results in a 
complete abolishment in CSR, as well in SHM (see section 1.4) in mice
60
 and in humans.
62
  
The processing of AID-induced Us by proteins from the base excision repair (BER) and 
mismatch repair (MMR) pathways may result in DSB formation (Fig. 4).
51
 Accordingly, 
mouse cells double deficient in the BER protein uracil-DNA glycosylase (UNG) and the 
MMR factor MSH2 are not able to undergo CSR.
63
 These repair pathways, which normally 
repair mismatches and small lesions in the DNA, have been “reprogrammed” by the immune 
system to create diversity. First, UNG removes the U to form an abasic site, which is 
recognized by the endonuclease APE1, which produces a ss break (SSB). If two SSBs are 
located close to each other on opposite strands, these could thus form a DSB, which could 
either be blunt or contain overhangs. The MSH2/MSH6 heterodimer could also recognize the 
U/G mismatches and thereafter recruit the MLH1/PMS2 complex, followed by EXO1 that 
binds to a nearby nick.
64
 EXO1, which can perform excision in both 3’ and 5’ direction, could 
then excise DNA until it reaches a nick on the opposite strand, which may result in a DSB.  
A prerequisite for this model is that AID binds to both DNA strands. The binding to the 
template strand, with less exposed ssDNA compared to the non-template strand, seems to be 
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facilitated by the RNA-exosome,
65
 a complex that processes/degrades RNA, possibly by 
removing RNA from the template strand. 
 
Figure 4. DNA double strand break formation through the actions of AID, base excision repair and mismatch 
repair proteins. AID initiates the process by converting cytosines into uracils. These mismatches are 
subsequently recognized by BER and MMR proteins, which form single stranded breaks (SSBs). Two SSBs that 
are close to each other on opposite strands may form a double strand break.  
1.3.2 Sensing by the DNA damage response 
DSB are immediately sensed by DDR factors that coordinate the cellular reaction to the 
break, such as checkpoint control and DNA repair
66,67
. In addition, several post translational 
modifications, including phosphorylation, acetylations, methylations and ubiquitinations are 
induced upon DSB formation
68
. The Mre11-Rad50-Nbs1 (MRN) complex rapidly binds at 
the vicinity of the breaks and activates P13-K kinases, including ATM and DNA-PKcs, 
which phosphorylates histone H2AX into -H2AX69. This modification is recognized by 
MDC1, which is recruited to the break and attracts the ubiquitin E3 ligases RNF8 and 
RNF168, which perform ubiquitinations that facilitate the recruitment of 53BP1 and BRCA1. 
Several DDR factors are important for CSR.  
1.3.2.1 ATM 
ATM is a Ser/Thr kinase that activates several DDR factors upon DSB formation.
70
 ATM-
deficiency in humans cause ataxia telangiectasia (A-T, described in section 1.6.3). These 
patients suffer from immunodeficiency and often present with low IgG and/or IgA levels, 
which may indicate a CSR defect.
71
 In addition, ATM-deficient mice are immunodeficient 
and show impaired CSR.
72,73
 A role for ATM in the repair of DSBs during CSR has also been 
revealed by the observations of increased MH usage at Sμ-Sγ1 junctions in mice72 and at Sμ-
Sα and Sμ-Sγ junctions from A-T patients.74 As ATM is involved in the 
phosphorylation/recruitment/activation of numerous DNA repair proteins, including -H2AX, 
53BP1 and Nbs1, ATM is likely to affect CSR through several mechanisms. 
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1.3.2.2 The MRN complex 
The MRN complex consists of the Mre11, Rad50 and Nbs1 proteins and Mre11-deficient 
patients show a reduced CSR efficiency.
75
 Furthermore, the S-S junctions from Nbs1-
deficient patients show increased MH usage, although not to the same level as those derived 
from cells from A-T-patients, indicating an involvement of this complex in CSR.
75
 
1.3.2.3 H2AX, MDC1, RNF8 and RNF168 
H2AX is a variant of histone H2 and is phosphorylated after DSB formation in the chromatin 
surrounding the break. It initiates the recruitment of several other DDR factors, including 
MDC1, RNF8, RNF168, 53BP1 and BRCA1. Both H2AX-
76
 and MDC1
77
-deficient mouse 
cells show mild CSR defects and an accumulation of IgH locus breaks.
78
 RNF8-
79
 and 
RNF168
80
-deficiency also cause CSR defects in mice.
81
 Furthermore, two RNF168-deficient 
patients have been described to date and both presented with low levels of certain Ig 
classes.
82,83
 Moreover, in Paper III we show that the S-S junctions from one of the 
RNF168-deficient patients exhibited increased MH usage
84
 and a similar pattern at the S-S 
junctions from the second patient has also been described.
83
 
1.3.2.4 53BP1 and RIF1  
CSR levels in 53BP1-deficient mice are only 2-10% of those in wild type mice.
85
 Thus, 
deficiency in 53BP1 confers the most severe CSR defect compared to all DDR factors. 
Furthermore, 53BP1-deficient mice show increased numbers of IgH locus breaks
78
. It is still 
not fully understood why 53BP1 has such a great impact on CSR. However, two central 
functions of 53BP1 in CSR have been proposed: in promoting synapsis between distant S 
regions
86
 and preventing end resection.
87
 The importance of 53BP1 and its effector molecule 
RIF1 in preventing resection, which seems to favor the usage c-NHEJ instead of HR, has 
been elucidated in several papers in recent years.
88-91
 The prevention of resection could also 
steer the repair during CSR to c-NHEJ, whereas inhibit A-EJ pathways.
87
 
1.3.2.5 BRCA1 
The gene encoding BRCA1 (Breast cancer, type 1 susceptibility protein) was discovered in 
1994 as a breast and ovarian cancer susceptibility gene.
92
 BRCA1 has been implicated in 
numerous processes involved in maintaining genome integrity, including checkpoint control, 
chromatin remodeling, transcription and HR.
93-95
 The BRCA1 protein can form complexes 
with various proteins through its different domains. BRCA1 contains an N-terminal RING 
domain with E3 ubiquitin ligase activity, binding to BARD1, a coiled-coil domain, 
interacting with PALB2 and BRCA2 and two C-terminal BRCT repeats, which forms the A, 
B and C-complexes through interaction with Abraxas, BRIP1 and CtIP, respectively.
93
  
One of the main functions of BRCA1 seems to be in repair pathway choice, by promoting HR 
during the S/G2 cell cycle phases.
88-91
 Although BRCA1 is considerably more prevalent at 
DSBs during S/G2 phases, when HR is active, it also accumulates at DSBs during the G1 cell 
cycle, albeit at lower levels.
96
 Despite its role in promoting HR, several in vitro studies have 
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suggested an involvement for BRCA1 in the NHEJ pathway,
97-100
 although this function has 
been controversial.
93,101
 BRCA1 could possibly affect NHEJ by stabilizing the binding of 
Ku80 to DSBs
96,102
 and by modulating resection.
100
 In Paper III, we show that CSR-junctions 
from BRCA1-deficient B-cells contain several alteration, including increased MH usage and 
intra-switch deletions, suggesting that BRCA1 affects the repair during CSR.
84
 
1.3.2.6 The cohesin complex 
The cohesin complex was first discovered as the proteins responsible for sister chromatid 
cohesion.
103,104
 Later, cohesin has been attributed with an expanding number of functions, 
from regulation of transcription through facilitating long-range chromosomal interactions
105
 
to chromatin condensation and DNA repair.
106
 
The multiprotein complex, cohesin, consists of two SMC 
(structural maintainance of chromosomes) subunits SMC1A and 
SMC3, a kleisin protein RAD21 and SA1/SA2, which are 
conserved from yeast to human.
107
 These are believed to form    a 
ring-shaped structure that could encircle DNA (Fig. 5). Several 
cohesin-associated factors have also been found, including the 
nipped-b-like protein (NIPBL), which loads cohesin to the 
chromatin.
107
 
Already before cohesin was shown to be involved in sister chromatid cohesion, it was 
observed that RAD21-deficient yeast cells were sensitive to -irradiation and exhibited a 
DNA repair defect.
108
 The role of cohesin in DNA repair has mainly been linked with HR, as 
its ability to hold sister chromatids together is believed to facilitate this process, which is 
dependent on the close contact between the chromatids.
109
  
In Paper I, we show that the S-S junctions from NIPBL-deficient patients exhibited  
increased MH usage, indicating that the repair process during CSR was impaired in these 
cells.
110
 Moreover, a link between cohesin and CSR has been presented in a study published 
in the same issue as Paper I.
111
 The cohesin subunits smc1 and smc3 (mouse counterparts to 
SMC1A and SMC3) were shown to be recruited to the S region during stimulation of CSR 
in mouse B-cells.
111
 Furthermore, the CSR efficiency was reduced in a CH12 mouse B cell 
line treated with siRNA for NIPBL or genes encoding cohesin subunits.  
The involvement of cohesin in transcription seems in part to function through its binding to 
the CCCTC-binding factor (CTCF) and these proteins can mediate long-range genomic 
interactions.
112
 Cohesin/CTCF can both promote and block transcription, by facilitating 
promoter/enhancer interactions or by insulating such contacts, respectively.
109
 Several CTCF 
binding sites have been found at the mouse Igh locus and RAD21 have shown a lineage 
dependent binding to these.
113,114
 Moreover, locus contraction was impaired in the absence of 
CTCF
113
 and it has been suggested that cohesin could be involved in this process.
115
 In 
addition, RAD21 has been shown to bind to several TCR cis-elements, including the E 
Figure  5. The cohesin complex 
The cohsin subunits may form a 
ring structure that could encircle 
DNA 
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enhancer, and was involved in regulating transcription and H3K4me3 histone modifications, 
which facilitates RAG recruitment.
116
 
1.3.3 Repair by the non-homologous end-joining pathway 
Similar to V(D)J recombination, CSR occurs during the G1 cell cycle phase.
117
 Furthermore, 
AID, like the RAG complex, has been shown to steer the repair of the DSBs towards the 
NHEJ pathway though the interaction with several NHEJ factors to its C-terminal end.
118,119
 
Deficiency in any of the c-NHEJ proteins seems to confer a CSR defect to various degrees. 
1.3.3.1 Ku70/80 
The Ku70/80 heterodimer encircles the DNA ends (Fig. 6) and forms a scaffold for 
subsequent recruitment of c-NHEJ factors. Ku-deficient mouse cells show CSR levels of 20-
50% of those in wild type cells.
120
 Furthermore, the CSR-junctions from Ku70-deficient 
mouse cells exhibited increased MH usage, but the repair by direct end-joining was not 
completely lost.
121
 
1.3.3.2 DNA-PKcs 
DNA-PKcs is a Ser/Thr kinase and the catalytic subunit in the DNA-PK complex, also 
containing the Ku70/80 heterodimer.
122
 The role of DNA-PKcs in CSR has been unclear with 
studies showing various effects of DNA-PKcs-deficiency on CSR efficiency.
123-128
 Only one 
of the studies analyzed the repair pattern at CSR junctions and did not find any alterations.
126
 
However, in Paper IV we show that the CSR-junctions from DNA-PKcs-deficient patients 
have increased MH usage. Possible functions of DNA-PKcs in CSR could be to activate the 
Artemis activity,
127
 as well as in DNA end synapsis.
129
 
1.3.3.3 Artemis 
Studies in both mice
127,130
 and in humans
131
 have shown an involvement of Artemis in CSR. 
Furthermore, Artemis-deficient mouse B-cells exhibit more AID-dependent IgH locus breaks 
than control B-cells.
127
 Artemis has been proposed to be involved in the processing of DNA 
ends during CSR by cleaving overhangs.
131
 The S-S junctions in patients show a complete 
lack of direct end-joining at S-S junctions and an increased usage of long MHs.131 
However, S-S1 junctions are normal both in mouse130,132 and in humans.131 Although an 
increase in Sx-Sysequential switching, which could be a characteristic of impaired NHEJ, 
has been observed in Artemis-deficient human cells.
131
 
1.3.3.4 Lig4/XRCC4/XLF  
Lig4, XRCC4 and XLF (Cernunnos) are involved in the ligation step of the DSB ends.
35
 
Whereas Lig4 performs the ligation, XRCC4 is required for its stabilization.
133
 The 
interaction between Lig4 and XLF is slightly weaker, but the addition of XLF to the complex 
increases the ability to ligate incompatible ends.
35
 Furthermore, XLF and XRCC4 have 
recently been shown to form filaments, which have been suggested to support end 
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bridging.
134
 The complete loss of XRCC4
135
 or Lig4
136
 is embryonic lethal in mice, which 
seems to be conferred by the importance of these proteins during neurological development. 
XRCC4
137,138
 or Lig4
121,139
 have thus been conditionally deleted in mouse B-cells and these 
showed reduced CSR efficiency. The repair patterns at CSR-junctions from XRCC4-
137
 or 
Lig4-
121
 deficient mouse B-cells were characterized by severely reduced or no direct end-
joining and increased usage of longer MHs. XLF-deficient mice are, on the other hand, 
viable
47
 and their B-cells only show only a mild defect in CSR.
47
 A shift to MH-mediated 
repair has also been observed at S-S junctions from Lig4-140 and XLF-141 deficient 
patients.  
Recently, a new protein with structural similarity to XRCC4, PAXX (PAralog of XRCC4 and 
XLF), was discovered.
142,143
 PAXX was shown to interact with Ku80 and to bind to XRCC4 
and XLF during ligation. However, no PAXX-deficient patients or mouse models have been 
described and it has not yet been investigated whether PAXX is, as XRCC4 and XLF, also 
involved in CSR. 
 
Figure 6: Proposed model of repair of AID-induced DSBs during CSR. The DSBs are sensed by DDR factors 
that recruit DNA repair proteins to the break site. The immediate binding of the Ku proteins steers the repair 
towards c-NHEJ. Thereafter the two DNA ends are synapsed, a process seemingly dependent on DNA-PK 
complex and DDR factors. If the DNA ends are not blunt, these might be processed by Artemis and DNA-PKcs, 
before the Lig4/XRCC4/XLF complex can ligate the two DNA ends. 
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1.3.4 Repair by alternative end-joining 
Indications of an A-EJ pathway arose from studies in yeast
144
 and mammalian
145
 cells, 
showing that even under c-NHEJ-deficient conditions, linearized plasmids could be repaired, 
although preferentially through MHs. A-EJ is not clearly defined and it has been debated 
whether it is a distinct pathway,
37
 reliant on a set of “alternative” factors, or whether it is 
merely an adaption of c-NHEJ, dependent on the missing c-NHEJ protein/s.
35
 The terms A-
EJ, MH-mediated end-joining
146
 and back-up end-joining are frequently intermingled.
37
 
Although A-EJ often relies on longer MHs, which could possibly reduce the dependence on 
certain c-NHEJ factors,
35
 MHs are not always present.
121
  
         
It is still not fully elucidated how the choice between HR, c-NHEJ or A-EJ is determined. 
Nevertheless, the decision between HR and c-NHEJ seems to depend, in part, on the cell 
cycle phase and the amount of resection around the break. Whereas HR requires extensive 
resection, long resections could impair the repair by c-NHEJ
88-91
. A-EJ also seems to depend 
on resection, possibly to reveal sequences for MH-mediated repair. Thus, 53BP1, which has 
been implicated in repair pathway choice between c-NHEJ and HR, could have a similar 
function in the decision between c-NHEJ and A-EJ
87
.  
A number of proteins have been implicated in A-EJ (Fig. 7). Poly(ADP-ribose) polymerase 1 
(PARP1) seems to be one of the central players in A-EJ, as it competes with Ku70/80 for 
binding to the DNA ends, which could channel the repair towards A-EJ or c-NHEJ, 
respectively
147,148
. In addition, PARP1 has the ability to recruit other factors, such as XRCC1, 
Lig3 and the MRN complex to the breaks 
149
. Furthermore, analysis of CSR junctions in 
PARP1-deficient mouse cells revealed shorter MHs at these, suggesting a role for PARP1 in 
MH-mediated repair during CSR
150
. The end resection during A-EJ might be mediated by 
Mre11 and CtIP
37
. A role for CtIP in A-EJ during CSR was supported by the observation of 
CSR junctions with decreased MH usage from CtIP-deficient B-cells
151
. Polymerase theta 
(PolQ) was recently described as a new A-EJ factor
152,153
 and could facilitate MH-dependent 
repair
152,153
. Ligation may be dependent on Lig1 and/or Lig3, as well as XRCC1
149
. 
Figure 7. Model of 
alternative end-joining. 
The binding of PARP1 
to the DNA ends would 
inhibit Ku binding and 
c-NHEJ. Mre11 and 
CtIP could resect the 
ends to reveal MHs, 
which could be 
recognized by PolQ. 
The ends might be 
ligated by Lig1 or 
Lig3/XRCC1.  
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1.4 SOMATIC HYPERMUTATION 
Although V(D)J recombination creates a highly diversified antibody repertoire it is not 
sufficient to produce antibodies that bind with high affinity to all possible antigens.
154
 Thus, 
antibodies undergo a second germinal center-dependent diversification process: SHM.
154
 This 
event, similar to CSR, is initiated by AID, which then targets the V regions and the 
processing of U/G mismatches will instead result in the creation of point mutations or small 
insertions and deletions. The mutation rate during SHM (~10
-3
/generation)
154
 greatly exceeds 
the mutation rate in normal cells (~2.5x10
-8
/generation).
155
 
Similar as for V(D)J recombination and CSR, transcription is required for SHM. However, 
the V regions are not as G rich as the S regions and transcription through V regions do not 
promote R-loop formation.
55
 SsDNA needed for AID binding is thus created only by the 
transcription process itself and SHM is consequently a slower process; SHM requires weeks, 
whereas CSR occurs withiin a few days.
55
  
During SHM, mutations at adenine/thymine (A/T) and G/C positions occur at roughly equal 
frequencies.
154
 SHM is divided into two phases depending on whether the mutations occur at 
G/C sites (Phase 1)  or at A/T sites (Phase 2)
156
 (Fig. 8). During phase 1a, replication across 
the U/G mismatch can create C-T and G-A transitions. Phase 1b is dependent on proteins 
from the BER pathway. Then UNG can excise the Us and subsequently recruit translesional 
polymerases, such as Rev1.
154
 During the second phase, MMR proteins seem to process the 
U/G mismatches and recruit error prone polymerases, including polymerase eta, which is 
known to cause mutations at A/T base pairs. Mice deficient in MSH2 thus have reduced 
mutations at A/T sites.
63
  
 
Figure 8. Model of somatic hypermutation 
AID induced uracils may be replicated over (Phase 1a), or recognized by the BER (Phase 1b) or MMR (Phase 2) 
pathways to create mutations at G/C and A/T sites. 
 
1.5 GENE CONVERSION 
Gene conversion is a third AID-mediated Ig diversification process, which occurs in 
chickens, rabbits and other large farm animals. A stretch of 25 pseudo-V genes, without 
promoters, enhancers and with frequent 5’ and 3’ truncations, is located upstream of the 
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functional V genes in the Ig locus of these animals.
157
 During gene conversion, pieces of 
pseudo-V genes are inserted into the V region
158
 and, in contrast to CSR, it is dependent on 
the HR pathway. Consequently, loss of BRCA1 in chicken DT40 cells resulted in reduced 
gene conversion in these cells.
159
  
 
1.6 PRIMARY IMMUNODEFICIENCY DISORDERS 
 
Primary immunodeficiency disorders (PID) are often caused by monogenic defects in 
components of the immune system and are associated with high morbidity and mortality if 
untreated.
160
 Over 200 distinct PIDs have been described to date.
161
 A subset of these is 
caused by defective DDR or DNA repair
162
 and some of these disorders, related to the thesis, 
will be discussed below 
 
1.6.1 Severe combined immunodeficiency 
Severe combined immunodeficiency (SCID) is one of the most severe forms of PIDs and is in 
most cases fatal without treatment.
163
 It is a rare disease affecting 1:50 000-1:100 000 live 
births. However, data from newborn screening programs in USA indicate that this might be a 
conservative estimation and that SCID is more prevalent in certain ethnic groups.
164
 SCID 
patients have defects in the adaptive immune system, which always involve T-cells and in 
some cases also B- and/or NK-cells. The patients suffer from recurrent infections, which are 
not cleared without treatment. 
SCID has a genetic basis and mutations in various genes involved in B- and T-cell 
development have been found in SCID patients.
165
 Four main mechanisms behind the disease 
have been described. These include premature cell death of lymphocyte precursor cells, 
defects in the signaling though the -chain dependent cytokine receptors, defective pre-TCR 
to TCR signaling and V(D)J recombination defects.
165
 A subset of the latter group is 
associated with radiosensitivity (RS) and these patients have mutations in genes encoding 
NHEJ factors.
166
 Until now, RS-SCID has been reported in patients with mutations in Lig4, 
XLF, PRKDC (encoding DNA-PKcs) and DCLRE1C (encoding Artemis).
166
 Lig4- and XLF-
deficient patients and one case of DNA-PKcs-deficiency
167
, in addition, presented with 
developmental and neurological problems.
166
 Recently, several patients with XRCC4-
deficiency have been reported.
168-171
 However, none of these patients were diagnosed with 
SCID or even immunodeficiency. Instead they were suffering from developmental and 
neurological malfunctions.
169
 If this is due to a dispensable role for XRCC4 during V(D)J 
recombination in human cells, or if residual XRCC4 activity in the patient’s cells is sufficient 
to perform V(D)J recombination, has not been determined.  
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1.6.1.1 DNA-PKcs-deficiency 
Two patients with DNA-PKcs-deficiency have been described to date. The first patient 
carried homozygous mutations in PRKDC that seemed mainly to affect its Artemis-activation 
function.
172,173
 This patient suffered from RS-SCID, but did not show any other 
abnormalities, and resembled the clinical presentations in previously described Artemis-
deficient patients.
166
  The second patient instead carried compound heterozygous mutations in 
PRKDC of which one seemed to completely inactivate DNA-PKcs, whereas the other caused 
severely reduced DNA-PKcs protein levels and barely detectable kinase activity.
167
 In 
addition to SCID, this patient was dysmorphic, suffered from severe growth failure and had 
neurological problems and microcephaly. The neurological malfunction was more severe 
than those observed in other c-NHEJ-deficient patients.  
 
1.6.2 CSR-deficiencies 
CSR-deficiencies, also known as hyper-IgM syndromes, are characterized by elevated or 
normal IgM levels, whereas absent or low levels of IgG, IgA and IgE and are often 
accompanied with a defect in SHM.
174
 These are rare disorders affecting around 1:100 000 
births.
174
 CSR-deficiencies can be caused by defects in B-cell activation, such as in patients 
with mutations in the genes encoding CD40 or CD40 ligand.
175
 Other subtypes are due to 
impaired functions of proteins important for the CSR process itself, including Ig-CSR 
deficiency 1, which is caused by mutations in AICDA (encoding AID) and affects both CSR 
and SHM.
62
 A subclass of AID-deficiency is caused by mutations specifically affecting the 
C-terminal part of AICDA, which is only required for CSR, but not SHM, thus not 
complemented with a SHM defect. Ig-CSR deficiency 2 is caused by mutations in the gene 
encoding UNG, which is also important for both CSR and SHM.
174
 
In addition, a few patients with defects in DDR or DNA repair proteins and 
immunodeficiency that could imply a CSR-deficiency have been reported
162
. These include 
patients deficient in Nbs1
176
 or ATM
177
 (see section 1.6.3)  and the MMR proteins PMS2
178
 
or MSH6.
179
 In addition, a patient with homozygous mutations in MSH2 presented with 
childhood malignancy and IgA-deficiency.
180
 Furthermore, patients with MSH5-deficiency 
have been reported with low IgA levels and common variable immunodeficiency (CVID).
181
 
Two patients with homozygous or compound heterozygous mutations in RNF168 have also 
been described.
82,83
 The first patient was suffering from Riddle syndrome (radiosensitivity, 
immunodeficiency, dysmorphic features and learning difficulties).
83,182
 The 
immunodeficiency somewhat resembled a CSR-deficiency disorder as the patient had normal 
IgM, but low IgG levels and the IgA levels were within the normal range
182
. The second 
patient had low IgA levels, ataxia and microcephaly.
82
 Recently, CSR-deficiency, with a 
hyper-IgM phenotype, was reported in two patients deficient in INO80.
183
 INO80 was shown 
to co-localize with cohesin at the Ig locus and the authors suggested that the CSR-deficiency 
could be caused by defective INO80-mediated modulation of cohesin activity during CSR.
183
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1.6.3 Ataxia telangiectasia 
A-T is a recessive, autosomal disorder characterized by radiosensitivity, immunodeficiency, 
cerebellar ataxia, oculocutaneous telangiectasia (dilated blood vessels), growth retardation 
and increased risk of cancers.
70,71
 It is a rare disorder affecting approximately 1:149 000 
births in Sweden.
184
 A-T is caused by mutations in the ATM gene and whereas classical A-T 
is due to homozygous or compound heterozygous truncating or inactivating mutations, a 
milder form of the disease, variant A-T, are caused by mutations that leave some ATM 
activity.
70,71
 The immunodeficiency could affect both the humoral and cell-mediated 
immunity.
185
 There are some A-T-patients that present with decreased serum IgA and IgG, 
but normal IgM, suggesting a CSR-deficiency.
177
  
 
1.7 ADDITIONAL DISORDERS STUDIED IN THESIS 
 
1.7.1 Cornelia de Lange syndrome 
Cornelia de Lange syndrome (CdLS) is a developmental disorder affecting multiple 
systems.
186
 Typical clinical features include intellectual disability, gastrointestinal problems, 
growth retardation, malformations of the upper limbs and characteristic facial features.
186,187
 
Furthermore, recurrent infections, including otitis media, viral respiratory infections, 
pneumonia and sinus infections are common
188
 and are frequent causes of death in CdLS 
patients.
189
 Although most CdLS patients are not immunodeficient, patients with CVID, 
hypogammaglobulinemia and specific antibody deficiency have been described.
188
 
CdLS is a genetic disease caused by mutations, most often sporadic, in genes encoding 
members of the cohesin pathway.
187
 CdLS is rare and affects about 1:50 000 in the 
population, although the real number could be higher, since milder cases might escape 
diagnosis.
190
 The majority of patients have heterozygous mutations in the gene encoding the 
cohesin loader NIPBL. It seems as frameshift/nonsense mutations cause the classical, more 
severe disorder and missense mutations often result in a milder form, whereas splice site 
mutations cause a phenotype in between.
186
 In addition, CdLS patients with mutations in the 
genes encoding the cohesin subunits SMC1A, SMC3 and RAD21,
191
 as well as PDS5B,
192
 
which promote cohesin unloading, and HDAC8
193
, which deacetylates SMC3, have been 
reported.
186
 In about 30% of CdLS patients, no causative mutation has been found.
186
  
The clinical manifestations in CdLS patients are thought to be due to deregulated 
transcription, particularly during development.
187
 The role of cohesin in sister chromatid 
cohesion is likely to be essential for life, as no null mutations in the cohesin pathway have 
been reported, hence all patients seem to have some residual cohesin activity.
187
 However, 
other functions of cohesin, such as in DNA repair, might also contribute to the CdLS 
etiology.  
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1.7.2 Hereditary breast and ovarian cancer syndrome 
Breast cancer is the most common cancer type  in women worldwide.
194
 About 7% of breast 
cancers and 14% of ovarian cancer cases are thought to be caused by inherited germline 
mutations in tumor suppressor genes.
195
 The most well-known of these are BRCA1 and 
BRCA2 and individuals with deleterious mutations in these genes run an increased risk of 
developing hereditary breast and ovarian cancer syndrome.
195
 The estimated prevalence of 
pathogenic BRCA1 and BRCA2 mutations is approximately 1:300-800 individuals, although 
these mutations are more common in certain ethnic groups due to founder effects.
196
 BRCA1 
mutation carriers have an approximately 65% risk of developing breast cancer and a 39% risk 
of ovarian cancer before the age of 70.
197
 
Tumors in BRCA carriers are thought to develop according to Knudson’s two hit model, with 
the germline mutation being the first hit, whereas the second allele is inactivated in the 
tumor.
93
 The role of BRCA1 and BRCA2 in HR are believed to be significant for their tumor 
suppressive functions.
95
 However, why breast and ovarian tissues would be more sensitive for 
HR-defects is far from elucidated.
198
 An involvement of BRCA1 in the regulation of estrogen 
activity has also been suggested to affect breast and ovarian cancer development.
199
 No other 
genes with an equivalent importance for breast carcinogenesis as the BRCA genes have been 
found. However, several low-penetrance genes, including ATM, CHEK2, BRIP1, PALB2, 
PTEN and TP53 of which many belong to the HR pathway, have been reported.
200
 
Furthermore, RECQL, involved in the repair of DSBs, was recently described as a novel 
breast cancer susceptibility gene.
201
 
Knowledge about the mutation status of breast cancer patients could be useful when choosing 
therapy. In December 2014 the first BRCA1/2-targeted drug, the PARP-inhibitor Olaparib 
(Lynparza), was approved.
202
 PARP-inhibitors exploit the functions of the BRCA proteins in 
DNA repair, through a mechanism called synthetic lethality. PARP1 is important for the 
repair of SSBs, whereas BRCA1/2-deficient cells have defects in HR-mediated repair of 
DSBs. Thus, cells defective in both pathways will be overwhelmed by unrepaired DNA 
damage, resulting in death of the tumor cells.
203
 Furthermore, it has been suggested that 
PARP inhibition cause error-prone NHEJ-activity in HR-defective cells, which could also 
contribute to its cytotoxic effect.
204
 
Until recently, only mono-allelic mutations were reported in BRCA1 and as null mutations in 
BRCA1 cause embryonic lethality in mice,
205
 the occurrence of homozygous mutations was 
not expected. Nevertheless, two patients with bi-allelic mutations in BRCA1 have been 
described.
206,207
 Both patients carried one frameshift mutation and one missense mutation in 
the BRCA1 BRCT domain, thus leaving some residual BRCA1 function. The clinical 
manifestations of the patients resembled those that are found in patients with Fanconi anemia 
(FA). FA patients have bi-allelic mutations in genes encoding members of the FA pathway, 
including the BRCA1-interacting proteins BRCA2, BRIP1 and PALB2.
36
 In addition, the 
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first patient developed ovarian cancer at an age of 28 years, whereas the second patient was 
diagnosed with breast cancer at 23 years of age.  
 
1.8 LYMPHOMA 
Malignant lymphomas are tumors that are derived from the lymphoid cells, either B, T or NK 
lymphocytes.
208
 Lymphomas are traditionally divided into Hodgkin and non-Hodgkin 
lymphomas (NHLs), of which the latter is a diverse group of malignancies, which include 
about 75 percent of all lymphoma cases.
208
 The incidence of NHL gradually increased 
between the 1970s and late 1990s and has tripled in the population over 65 years within the 
last 25 years in the Western world.
208
 The reasons behind this rise are not fully understood, 
but might involve the acquired immunodeficiency syndrome (AIDS) epidemic, better 
diagnosis and age-related immunodeficiency
208
. About 95 percent of lymphomas are of B-cell 
origin
209
 and it seems to be due to the many DNA alterations that B-cells undergo during 
CSR and SHM.
209
 The most common lymphoma in the Western part of the world is diffused 
large B-cell lymphoma (DLBCL), which originates from clonal expansions during the 
germinal center reaction.
210
  
 
1.8.1 The role of lymphocyte receptor diversification processes in 
lymphoma development 
The first indications of a connection between Ig diversification processes and lymphoma 
development originated more than thirty years ago when translocations involving the Ig locus 
and the proto-onco-gene MYC were observed in lymphomas in humans
211
 and in mice.
212
  
The Ig/MYC translocations often cause an extreme proliferation of B-cells and development 
of malignancy when the MYC gene is put under the control of the strong Ig enhancers (E 
and/or 3’C).213 Later, similar translocations between the Ig locus and proto-onco genes, 
such as BCL2 in follicular lymphoma and BCL1 in mantle cell lymphoma, have been 
observed and is a hallmark of many lymphomas.
209
 The formation of cancer requires 
numerous genetic changes, nevertheless, these translocations appear to be important initiation 
events during the development of some types of lymphomas.
214
  
There is a need for DSBs for a translocation to occur and DSBs are intermediates during both 
V(D)J recombination and CSR. Thus, some of these translocations seem to happen during 
V(D)J recombination. The RAG enzymes target RSS located in the Ig and TCR loci, 
however, similar sequences, known as cryptic RSSs, are found elsewhere in the genome. 
Cryptic RSSs are occasionally bound by RAG, which could induce translocations and such 
translocations are frequently found in T-cell acute lymphoblastic lymphoma.
214
 Furthermore, 
CCND1/IgH translocations in mantle cell lymphoma and BCL2/IgH translocations in 
follicular lymphoma have both shown breakpoints close to the RSS sites near the V and J 
genes.
215
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Translocations may also be induced by AID. Accordingly, formation of c-myc/Ig 
translocations seems to require AID activity in mouse cells.
216,217
  AID appears to have more 
Ig off-targeting activity than the RAG enzymes and AID binding outside the Ig locus may 
also create mutations in the genome.
218
 Similar as the targeting to the Ig locus, off-target 
binding seems to be dependent on transcription. According to a study in mice, AID 
specifically targets promoter-proximal sequences with stalled RNA pol II.
219
 Another study 
found that AID targets super-enhancers and regulatory clusters in the cells from both mice 
and lymphoma patients.
220
 Furthermore, AID off-binding at super-enhancers seems often to 
occur at the focal regions of overlapping sense and antisense transcription.
221
 High levels of 
AID expression have been observed in Burkitt lymphoma, germinal center B-cell lymphoma 
and DLBCL, whereas lower levels have been found in subsets of follicular lymphoma and 
mucosa-associated lymphoid tissue lymphomas.
218
 
 
1.8.2 Alternative end-joining and cancer 
A-EJ is slower and less accurate compared to c-NHEJ and could increase the risk for 
alterations, such as deletions and insertions, at the recombined junctions.
35,37
 Furthermore, A-
EJ has been associated with translocations.
120,222,223
 Mice double deficient in p53 and certain 
c-NHEJ factors, such as Ku80, XRCC4, Lig4, DNA-PKcs or Artemis, develop B-cell 
lymphomas with translocations involving the Ig locus.
224
 Moreover, mutations in the c-NHEJ 
genes have shown to be associated with translocations involving the IgH locus in human B-
cell lymphomas.
225
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2 MATERIAL AND METHODS 
 
2.1 AMPLIFICATION OF CSR FRAGMENTS AND ANALYSIS OF CSR-
JUNCTIONS 
In papers I, III and IV, CSR fragments were PCR amplified and sequenced from in vivo 
switched B-cells and the repair pattern at the CSR junctions was subsequently analyzed. The 
nested PCR assay has been previously described for amplification of S-S and S-
S140,228 junctions. Genomic DNA, isolated from peripheral blood, was used as a template in 
a nested PCR reaction with a forward primer binding to the beginning of the S region (Fig. 
9a) and a reverse primer to the S (binding to either S1 or S2 due to sequence homology) 
or S (binding to either S1, S2 or S3) regions for amplification of S-S and S-S 
fragments, respectively. To increase the sensitivity and specificity, a second PCR, with 
primers located inside the first set of primers, was performed with the PCR1 product as a 
template. For amplification of S-Sfragments, the reverse primers were specific for either 
S1, S2 or S3 regions. Ten reactions were run in parallel and subsequently visualized on an 
agarose gel (Fig. 9b). The PCR products could be approximately 100-1500 bp in size, 
depending on the location of the breaks in the S regions, representing different CSR events. 
These were then gel purified (Qiagen, Hilden, Germany) cloned in to PGEM-T vector and 
transformed into DH5 cells and the resulting plasmids were later isolated by Qiaprep mini 
kit (Qiagen) and sequenced (Macrogen, Soeul, South Korea). A similar strategy for 
amplification of CSR-junctions from mouse cells were used with primers specific for the 
mouse S229, S230 and S1,2a,2b,3)231 regions. Genomic DNA from mouse intestine, 
spleen and blood were used as templates in the nested PCR. 
The CSR fragment sequences were subsequently aligned to reference S232 S226,233 or 
S57,234 sequences for determination of the repair pattern (Fig. 9c). If the two S regions were 
joined directly, without homology at the putative breakpoints, the repair pattern was 
nominated direct end-joining. Nucleotide(s) at the junction, not matching either S region, 
were assigned insertions, whereas a stretch of subsequent nucleotides at the recombined 
junctions, perfectly matching both S regions, were characterized as MHs. Furthermore, “foot 
prints” of intra-switch recombination and sequential switching events, as well as inversions 
can be found at the CSR-junctions (Fig. 9d). 
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Figure 9: Description of nested PCR-assay for amplification of CSR fragments and subsequent analysis of 
CSR junctions.  
a) During CSR, AID initiates DSB formation in S and a downstream S region. These are subsequently repaired, 
resulting in a recombination junction between the two S regions and an excision circle containing the intervening 
sequence. The forward primer is located in the S region, whereas the reverse primer is located in a downstream 
S region (here exemplified by S), which can amplify the recombined switch regions. b) The products from 10 
PCRs run in parallel are subsequently visualized on a gel and bands, representing CSR fragments, are cut out, 
purified, cloned into bacteria and the plasmids are subsequently sequenced. c) The sequences are aligned with 
reference S regions and the repair pattern is analyzed. Examples of repair by direct end-joining, insertion and 
MHs are shown. Direct end-joining is indicated by vertical line, insertion is underlined and MHs are marked by 
box. The dotted box highlights imperfect repeats, allowing for one mismatch. The position of break points are 
indicated by arrow heads. d) Examples of CSR-junctions showing signs of intra-switch recombination, 
sequential switching and inversion events are presented. Neg. cont.: negative control. 
 
2.2 IN VITRO NHEJ- AND V(D)J-ASSAYS 
Plasmid based in vitro NHEJ- (Papers I and IV) and V(D)J- (Paper II) assays, were 
performed in cell lines derived from the patient’s cells. The assays have been previously 
described
235
 and were modified by us.  
For the NHEJ-assay, the pDVG94 plasmid was cut with EcoRV and EcoR47III (Thermo 
Scientific, Vilnius, Lithuania) to be linearized with blunt ends (Fig. 10). It was then 
transiently transfected into fibroblast cells using Turbofect (Thermo Scientific). Forty eight 
hours after transfection, the cells were collected and DNA was isolated using DNeasy blood 
and tissue kit (Qiagen). The recombined junctions were PCR amplified with FM30 and 
DAR50 primers
235
 and the PCR products were gel purified by QIAquick gel extraction Kit 
(Qiagen). In the original assay, the relative frequencies of direct end-joining or repair by 6bp 
MH, facilitated by 6bp identical repeat sequences adjacent to the ends, was assessed by 
digesting the PCR product with BstXI. Here, to be able to perform a more precise 
examination of the repair pattern, the PCR products were cloned into PGEM-T vector, 
transformed into DH5 bacteria and the plasmids were subsequently isolated and sequenced 
(Macrogen, Soeul, South Korea). The repair pattern was analyzed by aligning the sequences 
with reference sequences. After sequencing the recombined NHEJ-junctions, other types of 
repair patterns than the previously described were revealed. These involved deletions, either 
associated with MHs (deletion + MH) or not (deletions only) (Fig. 11).  
For the V(D)J-assay, the circular pDVG93 plasmid (containing RSS sequences), as well as 
RAG1 and RAG2 plasmids were co-transfected into fibroblast cells and the same procedure 
as for the NHEJ-assay was followed, with a few exceptions (Fig. 10). For amplification of 
V(D)J-junctions, a nested PCR with primers NV05F (5’-
CTATAGGGGAATTGTGAGCGGATAACDG-3’) and DG147 in PCR1 and DG89 and 
FM30
235
 in PCR2 was performed. In the original assay, the PCR product was cut with NotI 
or NgoMI to assess the proportions of repair by unprocessed joining or 4 bp MH, enabled by 
4bp identical repeats at the DNA ends. Similarly to the NHEJ-assay, we have modified the 
method by cloning and sequencing the amplified recombination junctions. The RAG 
enzymes could cut the RSS sites and form blunt or staggered ends, depending on the position 
of the break at the hairpin (see section 1.2.2).The recombined junctions could exhibit similar 
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repair patterns as the NHEJ-assay (unprocessed, 4bp MH, deletion, deletion + MH) and, 
additionally, long insertions containing palindromic nucleotides, not observed in the NHEJ-
assay, was found in Artemis-deficient cells.  
 
Figure 10: Scheme of NHEJ and V(D)J assay.  
Whereas pDVG94 was cut before being transfected into cells for NHEJ-assay, the pDVG93 plasmid, containing 
RSS sequences, were co-transfected with RAG1 + RAG2 plasmids, to mimic V(D)J recombination.  
 
 
Figure 11. Examples of different repair patterns observed at junctions derived from NHEJ-assay  
Similar types of repair patterns were observed after transfection with V(D)J-assay, however, 4bp MHs instead of 
6bp MHs were used.  
 
 
2.3 HIGH THROUGHPUT SEQUENCING OF THE B- AND T-CELL RECEPTOR 
REPERTOIRES 
 
Sequencing of B-cell receptors by 454 
In Paper II, the B- (IgH) and T-cell receptors (TCR) were PCR amplified and sequenced by 
high throughput sequencing platforms.  
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For amplification of the IgH VDJ regions, a semi-nested PCR containing pools of forward 
primers, binding to the beginning of the different V gene families, and a reverse primer, 
binding to the ends of all J gene genes, were used
236
 (Fig. 12a). Genomic DNA isolated from 
peripheral blood was served as a template. The PCR1 product was subsequently used in a 
second PCR, containing the same primers, but with 10-base multiplex-identifier tails to 
enable pooling of 12 different samples for sequencing. The high-fidelity Phusion DNA 
polymerase was used to minimize the occurrence of PCR induced mutations. To increase the 
specificity of the binding, polymerase was added after a hotstart at 98°C (for 30s, hold at 
50°C). In order to produce sufficient DNA for sequencing, repeats of PCR1 (x8) and PCR2 
(x2) were performed for each sample. PCR products were gel purified using QIAquick Gel 
Purification Kit (Qiagen). Samples to be pooled for sequencing were mixed in equal 
quantities and concentrated using QIAquick PCR Purification Kit (Qiagen) before 
sequencing on the GS FLX Titanium Sequencer (Agowa GmBH, Germany).  
 
Analysis of gene usage, CDR3 parameters and SHM frequency and pattern 
For determining the amino acid sequence at the CDR3 regions, as well as the V-, D- and J 
gene usage, the IMGT/V-QUEST tool
237,238
 (www.imgt.org), allowing for indels, was used. 
The sequences were organized in an excel sheet for analysis of diversity, V-, D- and J-gene 
usage and CDR3 properties. Only sequences with unique CDR3s were used for gene usage 
analysis, to avoid the skew of large, clonal expansions. The sequences were visually 
inspected for chimeric events, which are artefacts that contain more than one V gene and are 
created during the PCR reaction.
239
 Sequences consisting of another V gene, than that 
assigned by V-QUEST, at the end, associated with the CDR3 region, were omitted from V 
gene analysis, as it could not be determined to be unique based on CDR3 sequence.  
To study the SHM pattern and frequency, IgH V gene sequences were aligned to the 
corresponding reference V gene sequence by IMGT/V-QUEST.
237,238
 Only unique, 
unproductive sequences were used for analysis. Chimeric sequences were omitted through 
the same procedure as for V gene analysis and in cases of chimeric events at the beginning 
of the sequence, this part was deleted.  
 
Sequencing of T-cell receptors by Illumina Hiseq2000 
For TCR repertoire analysis, a similar strategy as for IgH V gene amplification was used. 
However, cDNA was used as template and the TCR CDR3s were amplified using an 
amplicon-rescued multiplex nested PCR method with primers specific for the various V- 
and C-genes (iRepertoire, Huntsville, USA). PCR1 contained V- and C- gene specific 
primers, harboring the same end tag sequence that can bind to a communal primer, to allow 
the specific binding. The PCR1 product was used as template in PCR2, containing the 
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communal primer that performs the real amplification of the TCR V region sequences 
(Fig. 12b). 
 
Figure 12: PCR strategy for amplification of IgH and TCRV regions.  
a) Pools of forward primers, binding to the various V gene families, and a common reverse primer binding to all 
J genes are used in a semi-nested PCR for amplification of IgH V regions b) TCR V regions are amplified by a 
nested PCR. PCR1 contains primers, with the same tag at the end, specific for the various V and C region 
genes, whereas PCR2 contains a communal primer that binds to the same tag in all sequences to avoid PCR 
induced bias.  
 
The PCR2 products were visualized on an agarose gel and purified using QIAquick gel 
extraction Kit (Qiagen). Equal amounts of DNA with different barcodes were pooled for high 
throughput sequencing (Illumina HiSeq 2000, iRepertoire). Sequences were aligned to their 
germline V-, D- and C-genes by the Smith-Waterman algorithm and the V-, D- and J-genes 
were assigned according to the IMGT/GENE-SB reference directory. Sequences were filtered 
by SMART (Sequencing error, mosaic sequence, amplification, reference, frequency 
threshold) filter, which filters out sequencing artefacts, PCR artefacts including chimeric 
sequences, insertions, deletion and substitutions and CDR3s that present at exceptionally low 
frequencies were excluded. Analysis of diversity, gene usage and CDR3 characteristics were 
performed in excel.  
 
 
 
b. 
a. 
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3 AIMS 
 
3.1 GENERAL AIMS 
The overall aim of this thesis was to elucidate the molecular mechanisms operating during the 
antibody diversification events V(D)J recombination, CSR and SHM in human cells. These 
processes are dependent on DDR and DNA repair factors, as well as proteins involved in 
histone modifications and transcription. By studying antibody diversification in patients with 
mutations in genes encoding such proteins, we aim to learn more about these processes in 
human cells, as well as how these defects could affect the patients, particularly the function of 
their immune system.  
 
3.2 SPECIFIC AIMS 
 
I. The aim of Paper I was to understand the role of the cohesin loader NIPBL in DNA 
damage response and, in particular, if NIPBL had a function during the NHEJ 
process. Furthermore, we would like to examine whether NIPBL-deficiency had an 
impact during CSR in the patient’s B-cells. 
 
II. The focus of Paper II was to learn more about the invovlement of cohesin during 
antibody diversification by studying V(D)J recombination and SHM in the cells from 
patients with CdLS. We also addressed the question whether the increased frequency 
of infections in CdLS patients could be due to defects in these processes.  
 
III. The purpose of Paper III was to investigate the role of the tumor suppressor protein 
BRCA1 and the BRCA1 associated factors BRCA2, BRIP1, CtIP and RNF168 in the 
NHEJ process during CSR. We were also interested in whether BRCA1 is a tumor 
supressor for B-cell lymphomas.  
 
IV. The objective of Paper IV was to elucidate the function of DNA-PKcs in the NHEJ 
process during CSR by studying the only two DNA-PKcs-deficient patients described 
to date. Since these harbored different defects in DNA-PKcs, an additional aim was to 
reveal possible kinase -dependent or -independent functions of DNA-PKcs during 
NHEJ and CSR.    
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4 RESULTS AND DISCUSSION 
 
4.1 PAPER I.  
 
A regulatory role for the cohesin loader NIPBL in nonhomologous end joining during 
immunoglobulin class switch recombination 
 
The focus of this paper was to examine the role of NIPBL in DSB repair and particularly its 
involvement in the NHEJ pathway. To address these questions, cells from CdLS patients, as 
well as cell lines derived from the patient’s cells and yeast strains, were studied. The CdLS 
patients carried mutations in the gene encoding the cohesin loader NIPBL or the cohesin 
subunit SMC1A.  
 
4.1.1 Increased DNA damage sensitivity in NIPBL-deficient cells 
Sensitivity to DNA damage was examined in B-lymphoblastoid (LCLs) and fibroblast (FB) 
cell lines derived from 7 CdLS patients. In addition, LCLs and FBs from healthy controls, as 
well as patients deficient in ATM, XLF or ESCO2, required for establishment of cohesion, 
were studied. MTS proliferation assay was performed on cells treated with -irradiation (g-
IR), which induce DSBs, to test their viability after DNA damage. All CdLS cell lines 
showed reduced survival compared to control cell lines (Fig. 1 in Paper I). Cohesin has 
previously been implicated in the repair of DSBs by the HR pathway.
106
 However, 
examination of the cell cycle distribution revealed that most (62-88%) CdLS cells were in the 
G1 cell cycle phase, when HR is not operating. Therefore, we were interested in whether the 
second major DSB repair pathway, NHEJ, which is pivotal during G1, was impaired in the 
cells from the patients.    
                               
4.1.2 Altered repair pattern at S-S junctions from NIPBL-deficient B-cells 
As CSR occurs during the G1 cell cycle phase and depends on the c-NHEJ pathway, in vivo 
generated S-S junctions were amplified from the B-cells from the CdLS patients. In total, 
91 unique S-S junctions were analyzed from 7 CdLS patients with mutations in NIPBL. 
The repair by direct end-joining was reduced, whereas the usage of longer MHs (7-9bp) was 
increased at the junctions from the patients (Table I). A similar shift from the usage of direct 
end-joining to longer MHs has previously been observed in patients deficient in the NHEJ-
factors Lig4 or Artemis (Table I). Thus, these results suggest that the repair by NHEJ during 
CSR is defective in NIPBL-deficient cells. 
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4.1.3 Skewed repair pattern at recombined junctions from in vitro NHEJ 
assay 
To further study the impact of NIPBL-deficiency on the resolution of DSBs by NHEJ, an in 
vitro NHEJ assay (described in section 2.2) was performed in the CdLS FB cell lines. This 
assay revealed a shift from the repair by direct end-joining to the usage of longer MHs at the 
recombined junctions (Table 2 in Paper 1). To ascertain that this phenotype was caused by 
the NIPBL-deficiency in the patient’s cells, the assay was also performed in cells treated with 
NIPBL siRNA and these cells showed a similarly altered repair pattern. Thus, the NHEJ-
pathway appears to be affected in NIPBL-deficient cells, also in a context not involving CSR.   
 
Table I: Summary of S-S junctiona results from all patients studied in this thesis 
 Perfectly matched short homology  
 0bp      
Study subjects 
Direct 
end-
joining 
(%) 
Small 
insertions 
(%) 
1-3bp 
(%) 
4-6bp 
(%) 
7-9bp 
(%) 
≥ 10bp 
(%) 
Total no. of 
S. 
junctions 
BRCA1+/- 21(11)*↓ 40(18) 45(21)***↓ 32(15) 38(18)*↑ 38(18)***↑ 214 
BRIP1-/- 1(3) 2(6)*↓ 6(19) 11(35)***↑ 10(32)***↑ 1(3) 31 
CtIPSCKL2 2(14) 1(7) 3(21) 5(36)**↑ 1(7) 2(14) 14 
BRCA2+/- 4(14) 5(17) 10(34) 4(14) 2(7) 4(14) 29 
RNF168-/- 2(8) 2(8) 3(12)*↓ 7(27)*↑ 8 (31)**↑ 4(15)*↑ 26 
Controls 
(adult)b 
41(16) 56(22) 91(36) 29(11) 25(10) 14(5) 256 
        
NIPBL+/- 6(7)↓ 4(4)↓ 16(18) 14(15) 32(35)↑ 19(21) 91 
SMC1A-/- 5(10) 6(12) 13(26) 10(20) 10(20) 7(14) 51 
BRIP1-/-  8(17) 7(15) 7(15) 11(24) 9(20%) 4(9) 46 
BRCA2-/- 2(6) 9(29) 4(13) 5(16) 5(16%) 6(19) 31 
DNA-PKcsP1 2(5) 6(15) 3(8) 6(15) 9 (23)*↑ 13 (33)**↑ 40 
DNA-PKcsP2 0(0) 1(7) 1(7) 4(27) 4 (27)*↑ 5(33) 15 
P1+P2 2(4)*↓ 7(13) 4(7)*↓ 10(18) 13(24)*↑ 18(33)**↑ 55 
Artemis-/-c 0(0)**↓ 6(11)*↓ 10(19) 8(15) 9(17) 21(39)***↑ 54 
Lig4-/-d 0(0)*↓ 1(3)*↓ 7(23) 4(13) 4(13) 14(47)***↑ 30 
XLF-/-e 2(2)***↓ 16(19) 7(8)*↓ 12(14) 12(14) 35(42)***↑ 84 
Controlsf  
(1-13y) 
31(17) 42(23) 36(20) 29(16) 19(10) 26(14) 183 
a. Statistical analysis was performed using 2 test and significant differences are indicated in bold.  * p<0.05, ** p<0.01, 
***p<0.001. Study subjects shown on top of adult controls in table were compared to adult controls, whereas study 
subjects below were compared to controls with younger ages (1-13y). NIPBL+/- study group contained individuals with 
various ages and therefore differences that are significant to both control groups are marked in bold.  
b. Previously published S-S junctions from adult controls.84,131 
c. Previously published S-S junctions from Artemis-deficient patients.131 
d. Previously published S-S junctions from Lig4-deficient patients.140 
e. Previously published S-S junctions from XLF-deficient patients.141 
f. Previously published S-S junctions from controls with younger ages.110,131 y:years, bp: base pair  
 
4.1.4 Impaired NHEJ in yeast cells 
To test whether the involvement of NIPBL in NHEJ is evolutionary conserved, an NHEJ 
assay was performed in yeast cells deficient in Scc2, the yeast NIPBL orthologue. As Scc2 is 
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central for cell survival in yeast, a temperature sensitive Scc2 allele, Scc2-4, was used. Yeast 
carrying Scc2-4 were thus arrested in the G1 phase, by treatment with A-factor pheromone, 
and the temperature was changed to inactivate the Scc2-4 gene, while a DSB was created in 
the MAT locus by the activation of an HO endonuclease. This break could solely be 
repaired by NHEJ, as the regions that would be used for HR-mediated repair were deleted 
and the DSBs were induced on both alleles. The yeast carrying the Scc2-4 allele showed poor 
survival at a level comparable to yeast cells deficient in the c-NHEJ factor Lig4 (Fig. 3 in 
Paper I). Hence, the function of NIPBL in NHEJ seems to be evolutionary conserved. 
Discussion on the role of NIPBL/cohesin in NHEJ can be found in section 4.2.6.  
 
4.2 PAPER II 
 
Altered usage of 3’ proximal immunoglobulin variable genes in patients with the 
cohesinopathy Cornelia de Lange syndrome 
 
In Paper I, we showed that NIPBL is involved in the repair process during CSR. In paper II, 
we have continued the investigation of the role of NIPBL and cohesin in antibody 
diversification. V(D)J recombination and SHM were studied in 8 CdLS patients with 
mutations in either NIPBL (n=5) or the cohesin subunit SMC1A (n=3). Furthermore, 5 A-T 
patients, who are deficient in ATM, were examined. We were also interested in whether 
ATM, similar to 53BP1,
240
 could be involved in facilitating long range DNA-interactions 
during V(D)J recombination. 
 
4.2.1 Reduced IgH repertoire diversity in CdLS patients 
To study V(D)J recombination during IgH rearrangement in NIPBL- and SMC1A-deficient 
CdLS patients, the IgH V regions were PCR amplified from gDNA and sequenced by a high 
throughput sequencing platform (454). On average, 3863 sequences were obtained from each 
sample. To obtain an overview of the IgH repertoires, the IgH diversities were examined. 
Notably, both the IgH diversity (unique/total sequences), as well as the D50-values (the 
cumulative frequency of sequences that account for half of the repertoire) were reduced in the 
NIPBL- and SMC1A-deficient patients (Fig. 1 in Paper II). Thus, CdLS patients appear to 
have a reduced IgH diversity, as well as an IgH repertoire more skewed towards large clonal 
expansions than healthy controls.  
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4.2.2 Altered V gene usage in CdLS patients 
Studies in mice have shown an involvement of the cohesin complex during regulation of 
V(D)J recombination at both the IgH
113
 and TCR loci.116 It has also been suggested that 
cohesin could facilitate locus contraction, which enables the diverse usage of V genes 
throughout the AgR loci (Fig. 13). Mouse B cells deficient in factors involved in locus 
contraction, including Ikaros,
241
 Yin Yang 1
242
 and Pax5,
243
 have shown increased 
frequencies of 3’ proximal, but reduced usage of 3’ distal, V genes.    
 
Figure 13: Possible roles of cohesin during V(D)J recombination 
a) Cohesin could  regulate transcription through mediating promoter-enhancer interactions. b) The IgH locus is 
compacted, through the formation of loops throughout the locus during V(D)J recombination and cohesin has 
been suggested to aid this process. c) NIPBL- and SMC1A-deficient B-cells showed an increased usage of the 
most 3’ proximal V genes, which could possibly be caused by altered transcription (germline or antisense) or 
locus contraction in the cohesin defective cells. 
 
Thus, we were interested in whether the reduced IgH diversities in the patients could be 
caused by an altered V gene usage. The IgH V regions from the SMC1A-deficient cells and 
the NIPBL-deficient cells from the CdLS patients with the classical form of the disease, 
showed a skewed V gene usage, with increased frequencies of the proximally located genes 
(Fig. 13). A decreased usage of the middle genes was also seen in the SMC1A-deficient cells. 
This analysis was performed on unproductive sequences, which are not expressed due to 
frameshifts or premature stop codons, and therefore represent a repertoire that is less 
influenced by selection. Thus, these results indicate that this alterations are likely caused by 
changes in the V(D)J recombination process itself, rather than by the selection from antigens. 
The changed V gene usage could possibly indicate a defect in locus contraction in the cells 
from CdLS patients. However, the process is not likely to be completely ablated as distally 
located genes were still used. In addition, an involvement of cohesin in germline or antisense 
transcription might also be and underlying cause for the changed V gene frequencies. It could 
possibly be due to impaired insulator activity, resulting in increased transcription of the 
proximal genes, in CdLS cells
244
 (Fig. 13). 
     
a. b. 
c. 
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4.2.3 Reduced frequency of mutations in the IgH V regions in CdLS patients 
Subsequently, the SHM pattern and frequency in the IgH V regions from the B-cells of the 
CdLS patients were examined. The percentage of mutations was markedly lower at the V 
regions from CdLS patients compared to controls (Table II in Paper II). In addition, the 
substitution patterns at the V regions were analyzed. However, apart from a reduction in A-C 
mutations in the SMC1A-deficient group (Fig. 3 in Paper II), the mutation pattern was largely 
normal in the V regions from CdLS patients. Transcription levels have shown a correlation 
with SHM efficiency.
245
 One possibility could thus be that the role of cohesin in controlling 
transcription extends to the regulation of transcription during SHM. It would thus be 
interesting to study further whether transcription is decreased during SHM in CdLS 
patient’s cells. Moreover, another potential function of cohesin in SHM could be in 
inducing chromosomal conformational changes, as these appear to aid in opening up the 
locus in order to enable AID binding.
246,247
  
 
4.2.4 The TCR repertoire in CdLS and A-T patients 
The TCR repertoires were then analyzed in 3 NIPBL-deficient CdLS patients, as well as in 
5 A-T patients. The TCRV regions were amplified and sequenced by a similar method as 
the IgH sequences. However, cDNA was used as template and the amplified V regions were 
sequenced by the Illuminia HiSeq 2000 sequencing platform. On average, 6 220 839 
sequences from each sample were obtained by this method. The TCR diversities were 
slightly reduced in the CdLS patients and this trend was even stronger in the A-T patients 
(Fig. 1, Paper II).  
The TCR V gene usage was analyzed, but seemed to be less affected in the NIPBL-deficient 
cells, compared to the IgH V gene frequencies. Nevertheless, a slight trend towards reduced 
usage of proximal, whereas increased usage of distal, V genes was instead observed (Fig. 4 in 
Paper II). The TCR locus is considerably smaller in size compared to the IgH locus and it is 
possible that V(D)J recombination is differently regulated at the two loci. Furthermore, only 
mild CdLS patients were included in the TCR V gene analysis and the classical CdLS 
patients might have shown larger alterations. Thus, the TCR V gene usage should be studied 
in more CdlS patients to determine its role in the process.  
The A-T patients showed altered frequencies of several V genes, as well as a similar 
tendency, as the NIPBL-deficient cells, towards a decreased proximal, but increased distal V 
gene usage (Fig. 4 in Paper II). A more marked change, however, was observed in the J gene 
usage. The V gene proximal J1 genes were underused, compared to controls, whereas the 
frequency of J2 distal genes was increased in the ATM-deficient cells (Fig. 5 in Paper II). A 
similar shift between the usage of the J1 and J2 clusters have been observed in mouse cells 
deficient in certain cis regulatory elements, including the CTCF binding sites between the 
D1J1 and D2J2 regions,
248
 as well as the PD1 promoter.249 Thus, besides its function in 
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stabilizing the DNA ends during DSB repair,
42
 ATM might also have a regulatory function, 
affecting the accessibility of different TCR locus regions, during V(D)J recombination.  
 
4.2.5 Normal repair of coding joints in CdLS patients 
As we had previously shown that NIPBL affects the NHEJ repair during CSR, we were also 
interested in whether NIPBL is involved in the NHEJ-mediated repair of coding joints. 
Therefore, an in vitro V(D)J recombination assay (described in section 2.2) was performed in 
CdLS derived FB lines. Cells deficient in the c-NHEJ factors XLF or Artemis, known to be 
required for repair of coding junctions in human cells, were also studied. The repair pattern at 
the junctions from the NIPBL-deficient cells was largely normal, although a decreased 
frequency of 4bp MH was observed. In addition, no alterations were found at the in vivo 
coding junctions, suggesting that NIPBL does not largely affect NHEJ repair during V(D)J 
recombination.   
 
4.2.6 Paper I and II. What could be the mechanism behind the involvement of 
NIPBL in NHEJ? 
Cohesin had previously only been implicated in the repair through the HR pathway. 
Nevertheless, the results presented in Paper I showed that NIPBL-deficient cells had 
increased sensitivity to DNA damage and impaired capability to repair these by the NHEJ 
pathway. No cohesin-independent function of NIPBL has been described and the defect is 
thus likely due to impaired cohesin loading.  
The nearly normal repair pattern observed at the coding junctions from NIPBL-deficient cells 
might seem contradictory to the role of NIPBL in NHEJ during CSR. However, many DDR 
and DNA repair factors appear to have various impact on CSR and V(D)J recombination.
43
 
The RAG proteins are associated with both the coding and signal ends after the cleavage step 
and seem to facilitate the recombination of the DNA ends.
33
  AID probably does not have the 
same protecting effect on the DNA ends as the RAG complex. Repair of coding and signal 
ends might thus be less dependent on DDR factors, which during CSR could have an end-
tethering function.
43
 
According to a previous study, cohesin could be involved in the recruitment of 53BP1.
250
 
Furthermore, 53BP1-deficient mice have shown a quite mild V(D)J recombination 
defect,
85,240
 but severely impaired CSR. To test the hypothesis that cohesin affects NHEJ by 
impairing the recruitment of 53BP1 to DSBs, 53BP1 foci formation was investigated in the 
NIPBL-deficient LCLs. Notably, 30 min after treatment with -IR, the 53BP1 foci formation 
was significantly reduced in the NIPBL-deficient cells, compared to the control cells (Fig. 4 
in Paper I). Ninety minutes after -IR, this difference was no longer noticeable. This suggests 
that NIPBL is required for the early recruitment of 53BP1 to DSBs. Since 53BP1 seems to 
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promote c-NHEJ, as opposed to A-EJ, the impaired 53BP1 recruitment in NIPBL-deficient 
cells might thus shift the repair to A-EJ during CSR, as proposed in Fig. 14. Furthermore, 
NIPBL/cohesin could possibly facilitate the recruitment of other DDR or NHEJ factors 
during CSR, which could also influence the repair during CSR. In addition, cohesin might 
have additional functions during CSR, similarly as during V(D)J recombination, in the 
regulation of transcription and in promoting long-range DNA interactions,
111,115
 which could 
possibly affect AID targeting. 
Furthermore, an involvement of NIPBL in the repair of coding ends, through the recruitment 
of 53BP1, could be masked by functional redundancy with other proteins, as shown 
previously between 53BP1 and XLF in mouse cells.
49
 We have not tested the role of NIPBL 
during the repair of signal ends. The signal ends, however, appear to be even less dependent 
on DDR factors, possibly as they are extrachromosomal and seem to have a stronger 
association with the RAG enzymes compared to the coding ends.
33
 As the VDJ-assay used in 
Paper II mainly assess qualitative changes at the repair pattern, an assay that measures the 
efficiency of V(D)J recombination should also be performed in the NIPBL-deficient cells.  
 
4.2.7 Paper I and II. Could CdLS be an immunodeficiency disorder? 
The results presented in Papers I and II suggest that all three antibody diversification 
processes are affected in CdLS patients. Most patients deficient in c-NHEJ factors are 
presented with SCID,
166
 as c-NHEJ is central for the repair of DSBs during V(D)J 
recombination. Somewhat milder immunodeficiencies are observed in patients with defects in 
certain DDR factors, such as the immunodeficiency in A-T patients.
70
 In addition, the two 
reported RNF168-deficient patients had normal levels of IgM combined with either low IgG 
or IgA levels
82,83
 and patients deficient in the chromatin remodeling factor INO80 presented 
with a hyper-IgM phenotype.
183
 On the contrary, CdLS is not even considered an 
immunodeficiency disorder. However, a recent study suggests that CdLS patients suffer from 
recurrent infections that are sometimes fatal and immunodeficiency has been reported in 
selected patients.
188
 It seemed that the repair of coding joints during V(D)J recombination 
was not largely altered, whereas the repair during CSR was affected, in NIPBL-deficient 
cells. If CSR is impaired in the absence of NIPBL, how come not more patients show signs of 
immunodeficiency? Although both AID and the RAG enzymes steer the repair towards c-
NHEJ, V(D)J recombination appears to be more reliant on this pathway and A-EJ is often not 
operating even in the absence of c-NHEJ factors.
39
 However, the A-EJ pathway has been 
shown to be quite robust during CSR
120
 and could probably compensate defects in c-NHEJ to 
some extent. Furthermore, as long as CSR is not fully eliminated, the B-cells that have been 
able to switch could go through clonal expansions and produce Igs, which could possibly 
mask a partial CSR-deficiency.  
The study of IgH V regions in CdLS patients revealed a lower IgH V region diversity, a 
skewed V gene usage and decreased frequency of mutations in the IgH V regions. These 
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more subtle defects in antibody diversification, and possibly in TCR development, might also 
result in impaired immune responses to infections in the patients. CdLS is a disease with 
variable symptoms and depending on mutation status (gene and severity), as well as 
environmental triggers, more severe immune defects might be observed in certain patients. 
Hence, it should be considered that the increased infections detected in CdLS patients might 
not only be caused by anatomical abnormalities, but also by inborn immune defects.   
4.3 PAPER III 
 
Aberrant recombination and repair during immunoglobulin class switch recombination in 
human BRCA1-deficient B-cells 
 
In Paper III, we wanted to investigate the role of BRCA1 and BRCA1-interacting/associated 
proteins in NHEJ. Previous studies on the involvement of BRCA1 in NHEJ in vitro, have 
yielded conflicting results.
93
 The analysis of CSR junctions from BRCA1-deficient 
individuals’ B-cells could thus serve as a suitable model for determining whether the NHEJ 
pathway is affected in vivo in a physiological context. Fifteen patients with deleterious 
mutations throughout the BRCA1 gene, as well as patients deficient in the BRCA1 associated 
proteins BRCA2, BRIP1, CtIP and RNF168 were thus studied.  
 
4.3.1 Longer MHs at S-S junctions from BRCA1-, BRIP1-, CtIP- and 
RNF168 defective B-cells 
In total, 227 S-S junctions were characterized from BRCA1-deficient individuals. 
Analysis of the repair pattern at these, revealed a change from the usage of direct end-joining 
and short MHs (1-3bp) to the usage of longer MHs (>6bp) (Table I). Thus, it suggests a shift 
from c-NHEJ to A-EJ in BRCA1-deficient cells. Furthermore, the study subjects were 
grouped depending on whether their mutations had previously shown a specific effect on the 
BRCA1 protein (Table S2 in Paper III). As the CSR junctions from individuals with 
mutations affecting the BRCA1 BRCT domain showed alterations, we also included patients 
with defects in the BRCA1 BRCT interacting proteins BRIP1 and CtIP. The S-S junctions 
from these patients had increased usage of longer MHs, although not as long as observed at 
those from BRCA1-deficient cells (Table I). CtIP has been implicated in A-EJ and seems to 
promote resection.
151
 It was therefore somewhat unexpected that the junctions from CtIP-
compromised cells showed longer MHs. However, the patients in the study carried mutations 
resulting in the expression of both normal level of wild type protein and a C-terminal 
truncated variant.
251
 This mutation might thus not ablate resection completely, but rather 
affect the resection capacity favoring the slightly longer (4-6bp) MHs. The other BRCA1 
BRCT formation complexes have also been implicated in resection, particularly through 
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inhibiting the process.
100,252,253
 In summary, these results suggest that defects in BRCA1, as 
well as in BRCA1-interacting proteins, affect the repair by NHEJ during CSR. A potential 
function of BRCA1 in NHEJ could be to inhibit resection, which would favor c-NHEJ 
instead of A-EJ as proposed in Fig. 14. In addition, its role in stabilizing Ku80 binding
96,102
 
to DSBs, is also likely to influence CSR. 
Several recent studies have pointed out BRCA1 as a central player in promoting HR during 
the S/G2 phases by inhibition of 53BP1 and thereby NHEJ.
91,254,255
 This function of BRCA1 
might seem contradictory to its role in promoting c-NHEJ during CSR. However, this could 
reflect the versatility of BRCA1, as it seems to have many separate functions, depending on 
its interaction partners.
256
 The HR-defect in BRCA1-deficient cells appears to be partly 
caused by improper 53BP1 binding, which results in inhibition of resection and impaired HR. 
However, by knocking down of 53BP1 in BRCA1-deficient cells, the HR defect could be 
rescued.
254,255
 Whether the combined deficiency in BRCA1 and 53BP1 could have a similar 
rescue effect on NHEJ has not been studied. Hence, we decided to examine the CSR-
junctions from an RNF168-deficient patient, whose cells have shown defects in the 
recruitment of both BRCA1 and 53BP1 to DSBs.
82
 The repair pattern at the CSR junctions 
from RNF168-deficient cells showed an even stronger dependence on MHs, compared to the 
BRCA1-deficient cells (Table I). Thus, the combined deficiency in BRCA1 and 53BP1 does 
not appear to rescue c-NHEJ, but rather cause a more severe defect in the process (Fig. 14).   
 
4.3.2 Additional alterations at CSR-junctions from cells deficient in BRCA1 
or BRCA1 associated factors 
The CSR-junctions from BRCA1-deficient cells contained higher frequency of intra-switch 
deletions (ISDs), compared to controls (Table 2 in Paper III). ISDs occur when two DSBs 
within a homologous S region are joined, instead of between two heterologous S regions (Fig. 
9d). Increased ISDs have previously been observed in models deficient in several DDR or 
NHEJ proteins.
73,86,120,257
 The reasons behind increased ISDs are not fully understood, but 
ISDs have been suggested to represent impaired long-range joining of distally located S 
regions
86
 and/or uncontrolled resection from existing DSBs.
258
 As proposed earlier, BRCA1 
might be involved in preventing resection during NHEJ and in its absence more DSBs 
might be resected, resulting in S region deletions. BRCA1 has also been shown to affect 
chromatin remodeling
259
 and could possibly be involved in the long-range synapsis of S 
regions. 
In addition, unusual insertions containing inverted S region sequences (Table 2 in Paper III, 
Fig. 9d), which are extremely rare in control cells, were observed at several CSR-junctions 
from BRCA1-deficient cells. These were also found at elevated frequency in BRCA2-
deficient cells and BRCA1 and BRCA2 might therefore be involved in preventing inversions.  
Furthermore, the S-S junctions from BRCA1- and RNF168-deficient cells were analyzed. 
The repair pattern at these was not largely altered (Table S3, Paper III). However, the 
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frequency of sequential switching, indicated by junctions such as S-Sx-Sy, (Fig. 9d), was 
increased in the BRCA1-deficient (11% vs. 0% in controls) and RNF168-deficient (21% vs. 
0% in controls) cells. We have previously proposed that sequential switching could be 
another type of A-EJ mediated mechanism operating at S-S junctions.131 The homology 
between the S and S regions is much greater than between the S and Sregions The 
latter therefore serve as a less efficient substrate for A-EJ compared to the S and S 
regions.
260
 Hence, an S-S junction from an already switched B cell could be used as a 
template for switching to another IgG subclass, as the S regions share extensive homology 
and would be suitable substrates for A-EJ. 
 
Figure 14. Proposed models of contributions of BRCA1, RNF168 and cohesin in NHEJ during CSR. 
a) In normal cells, c-NHEJ is the dominant pathway and BRCA1, possibly in complex with unknown protein(s), 
and 53BP1 may inhibit resection and promote proper synapsis. In the absence of b) BRCA1 c) RNF168, 
resulting in impaired recruitment of BRCA1 and 53BP1, or c) cohesin, causing delayed recruitment of 53BP1, 
resection may be increased and thus shifting the repair towards A-EJ. Furthermore, the synapsis of DNA ends 
might be destabilized. 
 
4.3.3 Could BRCA1 have tumor suppressor functions during lymphoma 
development? 
BRCA1 is a well-known tumor suppressor gene, a function that seems particularly important 
in the breast and ovarian tissues. However, other cancers, including melanoma
261
 and 
colorectal cancer in patients below 50,
262
 have shown an association with BRCA1-deficiency. 
Whether defects in BRCA1 could confer increased risk of lymphoma is yet to be resolved. 
However, a few studies support such a claim. A meta-analysis on studies of carriers of 
mutations within the BRCA1/2 pathways found a largely increased risk for several 
hematological cancers, including mantle cell lymphoma and acute myeloid leukemia
263
, 
whereas another study found an increased risk of NHL in patients with certain 
polymorphisms in BRCA1 and increased body mass index.
264
 Additionally, a novel 
pathogenic mutation in BRCA1 was reported in a 56 year old woman who simultaneously 
suffered from breast cancer and DLBCL and later developed ovarian cancer
265
.  
a. 
b. c. d. 
 40 
 
 
Many lymphomas have characteristic gene rearrangements including proto-onco genes and 
the Ig locus.
209
 The many roles of BRCA1 in maintaining genome stability, as well as the 
aberrantly repaired CSR junctions observed in BRCA1-deficient B-cells, thus make BRCA1 
an attractive candidate as a tumor suppressor also for B cell lymphomas. In further support of 
this, BRCA1/p53-deficient mouse models,
205
 as well as mice deficient in the BRCA1-
interacting protein RAP80,
266
 often develop lymphoma. Consequently, we examined 
previously published coding genome sequencing data on 31 DLBCLs from our group,
267
 as 
well as unpublished data on additional 22 germinal center related B-cell lymphoma cases 
for mutations in BRCA1. We found a number of somatic and germline mutations or rare 
SNPs in BRCA1 in these samples, including a germline, pathogenic frameshift mutation 
(p.Q1111fs). Notably, the occurrence of rare SNPs or mutations in BRCA1 (including those 
with <1% frequency in the ethnically matched population) in our lymphoma cohort seemed to 
be increased compared to the reported frequency in the general population (Table III). A 
screening in a larger cohort would, however, be required to determine the contribution of 
defects in BRCA1 to lymphoma development.  
 
Table III: Comparison of frequencies of SNPs/mutations in BRCA1 between our lymphoma 
cohort and the general population  
Mutation in BRCA1 Frequency in lymphoma cohort
a
 
samplesa 
Frequency in population
b
 
c.4039A>G 0.019 0.001/0.001 
c.3333delA 0.019 Not reported 
c.571G>A 0.019 0.001/0.003 
c.5347A>C 0.019 Not reported 
All mutations combined
c
 0.076 0.004 
a. 53 individuals with lymphoma were screened for mutations in BRCA1.  
b. Allele frequencies in population from 1000 genomes in all ethnicities and in ethnicity matched to patient are 
shown. 
 
4.4 PAPER IV 
 
DNA-PKcs is required for immunoglobulin class switch recombination in human B-cells 
both through its kinase- dependent and independent activity 
 
The aim of Paper IV was to determine whether DNA-PKcs is involved in CSR in human 
cells. Studies on the role of DNA-PKcs in CSR in mouse cells have yielded conflicting 
results.
123-128
 Hitherto, only two patients with DNA-PKcs-deficiency have been 
described,
167,172
 whom showed different defects in DNA-PKcs (Table IV). In order to 
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understand more about the role of DNA-PKcs in NHEJ, a DNA-PKcs-deficient mouse model 
was studied. In addition, substrate switching in the Ramos B cell line treated with DNA-PKcs 
specific (NU7026) inhibitor (DNA-PKcsi) was examined.   
 
4.4.1 Altered repair pattern at CSR-junctions from DNA-PKcs-deficient cells 
Altogether, 56 S-S junctions were analyzed from the two DNA-PKcs-deficient patients. 
Similar to the B-cells deficient in the c-NHEJ factors Artemis,
131
 Lig4
140
 and Cernunnos,
141
 
the repair by direct end-joining was reduced, whereas the usage of long MHs was increased at 
the S-S junctions from the patient’s cells (Table I).  
Furthermore, the S-S junctions were analyzed. Whereas no junctions could be isolated 
from P2, 35 S-S junctions were characterized from P1. The repair pattern at S-S 
junctions was largely normal (Table S2 in Paper IV). However, the S-S junctions exhibited 
markedly increased sequential Sx-Sy switching events (37% vs. 2% in controls) (Fig. 9d) 
(discussed in section 4.3.2). 
As previous studies in DNA-PKcs-deficient mouse models have presented discrepant results, 
we also characterized 34 S-S junctions from DNA-PKcs-deficient mice. In agreement with 
the results on human cells, these also showed increased repair by long (7-9bp) MHs (38% vs. 
13% in controls). 
To further investigate the role of the DNA-PKcs kinase activity in NHEJ and CSR, substrate 
switching in Ramos B-cells cells treated with DNA-PKcsi was analyzed. The Ramos B cell 
line was stably transfected with the XF-5a plasmid,
268
 modified to contain the S and S 
or S3 regions (Fig. S2 in Paper IV). After stimulation with CD40 mAb and IL-4, the 
Ramos cells could undergo substrate switching and the CSR-junctions could be amplified 
and characterized in the same manner as from in vivo switched B-cells. The repair of S-S2 
junctions from cells without DNA-PKcsi treatment appeared to be shifted towards 
increased A-EJ in the Ramos system. Nevertheless, after addition of DNA-PKcsi, the S-
S2 junctions showed an even stronger skew towards A-EJ, implicating that residual c-
NHEJ activity in the Ramos B-cells was further repressed in the absence of DNA-PKcs 
kinase activity (Table V in Paper IV).  
Moreover, the S-S3 junctions were studied and these also showed increased MH usage, 
indicating a shift to A-EJ in the Ramos system. Nevertheless, although the repair by direct 
end-joining was reduced, it was not fully lost as observed at the S-S2 junctions. When 
adding DNA-PKcsi, however, the repair by direct end-joining was completely abolished 
(Table V in Paper IV).  
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4.4.2 Skewed repair pattern at recombined junctions from DNA-PKcs-
deficient cells transfected with linearized plasmid 
To clarify the role of DNA-PKcs in the NHEJ pathway, the plasmid based in vitro assay 
(described in section 2.2) was performed in FB cell lines derived from the patients. The 
recombined junctions, from P1 and P2 cells, exhibited a shift to the usage of A-EJ (reduced 
direct end-joining and increased MH usage). Furthermore, a repair pattern characteristic of 
deletions associated with MHs was observed at increased frequencies in the cells from P2, but 
not from P1. Thus, it seems as the cells from P2 harbor additional or more severe defects 
during NHEJ.  
 
Table IV: Overview of DNA-PKcs-deficient models studied in Paper IV 
DNA-PKcs-
deficient 
model 
Presence 
of protein 
Kinase 
activity 
Artemis-
activation 
Effect on 
S-S 
junctions 
Effect on  
S-S  
junctions 
Effect on plasmid 
based NHEJ-
assay 
P1 Yes Retained Impaired MH↑ 
Direct end-
joining↓ 
Sequential 
switching↑ 
Direct end-
joining↓ 
 6bp MH↑ 
       
P2 Reduced Impaired ? MH↑ 
No direct 
end-joining 
Could not be 
amplified 
Direct end-
joining↓ 
 6bp MH↑ 
Deletion+MH↑ 
       
DNA-PKcs-
deficient 
mouse 
Reduced Impaired ? MH↑ Could not be 
amplified 
NA 
       
Ramos + 
DNA-PKcsi 
Yes Impaired
a
 ? MH↑ 
 
No direct end-
joining 
NA 
a. The kinase activity was judged to be impaired based on the effect of addition of the inhibitor on CSR. 
P: patient, NA: not analyzed, DNA-PKcsi: DNA-PKcs inhibitor, MH: microhomology. 
 
4.4.3 What could be the kinase-dependent functions of DNA-PKcs during 
NHEJ and CSR? 
The DNA-PKcs-deficient models with impaired kinase activity exhibited additional or more 
severe effects compared to P1, whose cells had retained DNA-PKcs kinase activity (Table 
IV). Thus, it seems as DNA-PKcs has additional functions besides Artemis-activation during 
CSR, which might depend on its kinase activity. 
P2 cells showed increased frequency of deletions associated with MHs, which was not 
observed in the cells from P1, in the in vitro NHEJ assay. As deletions would occur by 
resections around the DSB ends, DNA-PKcs might block the access of the DNA ends to 
other proteins,
269
 thereby protecting them from end-processing before ligation.  
The addition of DNA-PKcsi to the Ramos system resulted in a full abolishment in direct end-
joining at the S-S junctions. A complete lack in direct end-joining at S-S junctions has 
previously only been reported in XRCC4-deficient mouse cells.
137
 Thus, DNA-PKcs, with 
inactive kinase activity, might affect the action of XRCC4, possibly through defective 
phosphorylation of XRCC4 and/or by preventing it from binding to the DNA ends. It seems 
 43 
 
as DNA-PKcs auto-phosphorylation is required for the protein to dissociate from the DNA 
ends.
270
 In normal cells, DNA-PKcs protein may shield the ends to prevent resection, 
however, if the protein does not eventually detach from the ends it might block the access of 
other proteins, preventing efficient ligation. Notably, DNA-PKcs kinase dead mice have 
shown a more severe ligation defect, resulting in impaired recombination of signal joints, 
compared to mice completely deficient in DNA-PKcs protein.
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 An illustration of the 
possible effects of the different DNA-PKcs-deficient models is shown in Fig. 15.  
Figure 15. Proposed model of the roles of DNA-PKcs in NHEJ during CSR.  
a) In normal cells, DNA-PKcs could activate Artemis, protect the DNA ends before ligation and promote 
synapsis of the DNA ends. b) In P1, mainly the Artemis-activation function seemed to be affected, which could 
result in defective end-processing. c) In P2, both protein levels and kinase activity was impaired, which could 
affect Artemis-activation, end-protection and synapsis. d) The addition of DNA-PK kinase inhibitors to the 
Ramos system might impair the dissociation of DNA-PKcs from the DNA ends, thus preventing efficient 
ligation.  
 
4.5 COMPARISON OF CLASS SWITCH RECOMBINATION JUNCTIONS IN 
HUMANS AND MICE 
Papers I, II and III contain the analysis of CSR junctions, which can serve as a useful tool for 
studying the influence of DNA repair proteins during CSR. Nevertheless, most studies of 
CSR junctions have been performed in mouse models.
51
 Although the human and mouse 
immune systems share many similarities, the two species separated more than 60 million 
years ago and many changes have occurred since then.
260
 For example, the mouse and human 
IgH loci differ regarding the number of C genes, enhancers and pseudogenes (Fig. 16).  
 
 
 
a. 
b. c. d. 
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Figure 16. The human and mouse IgH loci.  
The human and mouse IgH loci are different, such as the human locus contain two C region gene subclasses, 
two pseudo genes (unfilled rings) and two 3’1E enhancers. 
 
Since we are mainly studying CSR in human B-cells, it is important to understand whether 
results from mice are relevant for human conditions or vice versa. There are a few methodical 
differences between the CSR junction analysis performed in human and mice, which can 
make the comparison between the two difficult. While studies in human cells have mainly 
been focused on the S-S junctions, most studies performed in mouse cells have analyzed 
the S-S junctions. As discussed earlier, the deficiency in a repair protein can have very 
different effects on the repair pattern at S-S and S-S junctions. Furthermore, most 
studies on mice have analyzed CSR junctions from in vitro stimulated B-cells, which could 
potentially alter the repair pattern. The CSR junctions analyzed from humans, on the other 
hand, have most often been amplified from peripheral blood lymphoid cells, representing the 
in vivo switched B-cells. In order to facilitate the comparison between humans and mice, we 
have analyzed the S-S junctions from in vivo switched B-cells from three mouse models, 
corresponding to three DNA repair disorders that we have studied previously (Table V). The 
knock-out mice were compared to wild-type mice with the same background strain and with 
same age, since we have previously shown that the MH usage differ at CSR-junctions from 
individuals with different ages.
51
 
 
                       Table V. Patients and mouse models included in comparison 
Human disorder Mouse model 
Ataxia telangiectasia (ATM
-/-
) ATM
-/-
 
DNA-PKcs-deficiency (DNA-PKcs
-/-
) DNA-PKcs
-/-
 
Cornelia de Lange syndrome (NIPBL
+/-
) NIPBL
+/-
 
 
A comparison of the repair pattern from human control and mouse wild-type cells shows that 
the frequencies of different lengths of MHs are quite similar in the two species, although the 
repair by direct end-joining is somewhat higher in the mouse cells (Table VI). In addition, the 
different mouse strains exhibit some variations, such as the S-S junctions from the Cd1 
strain have decreased frequency of longer (>7bp) MHs, compared to the B6 and 129/Sv 
strains. Furthermore, the deficiency in DNA-PKcs or ATM appears to have similar effects at 
the S-S junctions from mouse and human cells, resulting in reduced direct end-joining, 
whereas increased usage of longer MHs (Table VI). However, this shift is less pronounced in 
the mouse compared to the human cells. The NIPBL-deficient mice, on the other hand, 
showed the same amount of direct end-joining as the wild-type mice, although a slight, non-
significant, increase in longer (4-6bp) MHs (Table VI).  
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To conclude, the repair patterns at the CSR junctions are largely similar between healthy 
human control and mouse wild-type cells. Furthermore, the deficiencies in repair factors, 
known to influence the repair pattern in human cells (ATM, DNA-PKcs and NIPBL), have a 
similar effect in mouse cells. However, the alterations appear to be more pronounced in 
human cells, therefore the results obtained from mouse models could not always be directly 
extrapolated to a human setting or vice versa. The S region compositions might be 
responsible for some of the variation between the species. Although the S and S regions 
are the most homologous S regions in both human and mice, the two S regions show even 
more similarity in humans than in mice.
260
 Thus, in the absence of c-NHEJ, the A-EJ would 
have less homologous substrates to use at the mouse Ig locus, which might result in a slightly 
weaker shift to long MHs. In addition, the involvement of various DNA repair factors, which 
could have evolved somewhat differently in the two species, might not be the same. One 
example is the c-NHEJ factor XLF. Whereas XLF-deficient patients have a CSR defect,
46
 
XLF-deficient mice show nearly normal CSR levels.
47
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Table VI. Characterization
a
 of S-S junctions from in vivo switched B-cells from A-T, 
DNA-PKcs-deficient and NIPBL-deficient patients, as well as in corresponding mouse 
models. 
 Perfectly matched homology  
 0bp      
 
Direct 
end-
joining 
(%) 
Small 
insertions 
(%) 
1-3bp 
(%) 
4-6bp 
(%) 
7-9bp 
(%) 
≥10bp 
(%) 
Total no. of 
S junctions 
Study 
subjects 
       
A-Tb 1(2)*↓ 1(2)**↓ 15(34) 9(20) 5(11) 13(30)***↑ 44 
Controls 
(adult) 
41(16) 56(22) 91(36) 29(11) 25(10) 14(5) 256 
DNA-PKcs-/- 2(4)*↓ 7(13) 4(7)*↓ 10(18) 13(24)*↑ 18(33)**↑ 55 
NIPBL+/- 6(7)↓ 4(4)↓ 16(18) 14(15) 32(35)↑ 19(21) 91 
Controlsc  
(1-13 years) 
31(17) 42(23) 36(20) 29(16) 19(10) 26(14) 183 
Controlsd 
(adult) 
41(16) 56(22) 91(36) 29(11) 25(10) 14(5) 256 
        
Mouse 
modelsb 
       
ATM-/- 
(129/Sv) 
2(8) 2(8) 4(16) 7(28) 6(24) 4(16) 25 
Wild-type 
(129/Sv) 
14(23) 10(17) 16(27) 9(15) 8(13) 3(5) 60 
DNA-PKcs-/- 
(B6) 4(12) 3(9) 6(18) 4(12) 13(38)**↑ 4(12) 34 
Wild-type 
(B6) 13(24) 8(15) 18(33) 7(13) 7(13) 1(2) 54 
NIPBL+/- 
(Cd1) 
5(25) 2(10) 8(40) 5(25) 0(0) 0(0) 20 
Wild-type 
(Cd1) 
5(25) 6(30) 7(35) 2(10) 0(0) 0(0) 20 
a. Statistical analysis was performed using 2 test and significant differences are indicated in bold.  * p<0.05, ** p<0.01, 
*** p<0.001. A-T and DNA-PKcs-/- patients were compared to controls with lower ages (1-13y). NIPBL+/- study group 
included individuals with various ages and therefore differences that are significant to both control groups are marked in 
bold.  
b. Previously published S-S junctions from A-T patients74. 
c. Previously published S-S junctions from controls with younger ages110,131. 
d. Previously published S-S junctions from adult controls84,131. 
e. The knock out mice were compared to litter mate wild type mice with same background strain (indicated underneath the 
mouse model) and age. bp: base pair 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
**↑ 
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5 CONCLUSIONS AND FUTURE PERSPECTIVES 
 
The aim of this thesis was to elucidate the roles of NIPBL, BRCA1 and DNA-PKcs in CSR 
and NIPBL and SMC1A in V(D)J recombination and SHM in human cells. The main 
conclusions are: 
 
I. NIPBL-deficient cells from CdLS patients show increased DNA damage. This seems 
in part to be caused by impaired NHEJ and the function of NIPBL in NHEJ  appears 
to be evolutionary conserved. NIPBL could be involved in NHEJ by facilitating the 
early recruitment of 53BP1 to DSBs.  
 
II. NIPBL- and SMC1A-deficient CdLS patients show reduced IgH V region diversity. 
This could in part be caused by a skewed V gene usage in the B-cells from the 
patients. Furthermore, the IgH V regions from the CdLS patients exhibit a reduced 
frequency of mutations. These defects in Ig diversification could be an underlying 
cause of the frequent infections in the patients. 
 
III. BRCA1 affects the repair by NHEJ during CSR. Furthermore, BRCA1-associated 
factors, including BRIP1, CtIP and RNF168 also seem to influence NHEJ. We 
suggested a previously unrecognized role of BRCA1 in B-cell lymphomagenesis. 
 
IV. DNA-PKcs is involved in CSR in human B-cells. Furthermore, deficient DNA-PKcs 
kinase activity seem to confer additional or more severe defects on the process.  
 
This work has shown that NIPBL, BRCA1 and DNA-PKcs are involved in the repair of 
DSBs during CSR. Still, there are many questions remaining regarding the CSR process.  
The discovery of AID about 15 years ago greatly increased the understanding of the 
molecular mechanisms of CSR. Since then, a myriad of proteins involved in diverse 
processes, ranging from histone modifications, transcription and the recruitment of AID to 
BER and MMR pathways, DDR and c-NHEJ, have been associated with CSR.
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Nevertheless, a coherent picture of the contributions of all the proteins is still missing.  
In addition, the A-EJ pathway is yet not fully understood. Whether A-EJ represents one or 
several pathways, or should not even be designated a pathway, is still open for debate. The 
factors implicated in A-EJ, such as PARP1, Mre11 and XRCC1, have functions in other 
repair pathways and do not seem to have developed specifically for A-EJ.
43
 A recent screen 
of A-EJ proteins support the notion that A-EJ employ repair proteins from diverse 
pathways.
273
 Furthermore, the newly recognized A-EJ factor Pol Q
152
 was previously known 
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to be involved in cross-linked repair and BER. As A-EJ is linked to translocations, it would 
be useful to obtain a deeper understanding of this type of repair and its role in carcinogenesis. 
Thus, the Ramos B cell line transformed to undergo substrate CSR, which showed a shift to 
A-EJ and employed in Paper IV, could be a useful system to learn more about this pathway.    
Another important question is to further clarify the role of antibody diversification processes 
in lymphomagenesis. This would include how AID is specifically recruited to the Ig locus. 
Many of the processes facilitating AID recruitment, such as transcription, occurs elsewhere in 
the genome and even though AID has Ig off-target activity, its occupancy at the Ig locus 
exceeds by far any other genomic location.
274
 In addition, it would be valuable to learn more 
about the influence of defects in proteins involved in antibody diversification for lymphoma 
development. Mutations in DNA repair genes are frequently observed in lymphoma 
patients
225
 and in Paper III several rare SNPs and mutations in BRCA1 were found in 
lymphoma patients. An increased knowledge of lymphoma risk genes/mutations could 
possibly be used for cancer screenings in those with increased susceptibility and thus the 
earlier discovery of lymphoma. Furthermore, as the newly approved PARP-inhibitor for 
treatment of breast and ovarian cancer in BRCA1/2 carriers have shown,
202
 the knowledge of 
mutation status and DNA repair pathways could be employed during development of new 
cancer therapies.  
In this thesis the analysis of CSR junctions has been a frequently used tool to study the 
impact of various DNA repair factors on CSR. Similar as the immune repertoire analysis has 
moved to the high-throughput sequencing methods in recent years,
275
 this might occur for 
CSR-junctions. High-throughput sequencing of translocations can now be performed
276
 and 
this method has currently been converted for the sequencing of CSR junctions in mice in Fred 
Alt’s lab at Harvard. Adapting this technology for human cells could enable the sequencing 
of thousands of CSR junctions in a single experiment within a short time period.   
A challenge when working with human samples could sometimes be the scarcity of material 
from rare patients, who might be children or possibly pass away during the study. Then, the 
novel CRISPR-Cas9 technology,
277
 which can make very precise modifications into the 
genome, could enable the creation of cell lines with patient-specific mutations. The in vitro 
NHEJ and V(D)J assays, used in this thesis, could possibly be performed in such cell lines, 
making it possible to study the effect of the mutations without sampling the patient.  
Furthermore, the expanding number of proteins found to affect antibody diversification offers 
new candidate genes for patients with PIDs, as the mutation status in most of these patients is 
still unknown.
278
 As recent trials for gene therapy to treat PID patients have shown promising 
results,
279
 the knowledge of the underlying genetic cause of these disorders might become 
even more useful in the treatment of patients in the future.     
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